%HPSHGRLF$FLGPJ(]HWLPLEHPJ
)L[HG'RVH&RPELQDWLRQ (VSHULRQ7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO)'& $PHQGPHQW0DUFK
&RQILGHQWLDO 3DJHRI 7,7/(3$*(
%(03('2,&$&,'(7& 0*(= (7,0,%(0*
),;(''26(&20%,1$7,21
)'&
$5$1'20,=(''28%/(%/,1'3$5$//(/*5283678'<72
(9$/8$7(7+(()),&$&<$1'6$)(7<2)%(03('2,&$&,'
0*(=(7,0,%(0* ),;(''26(&20%,1$7,21
&203$5('72(=(7,0,%($1'3/$&(%2,168%-(&76:,7+
7<3(',$%(7(6$1'(/(9$7('/'/&+2/(67(52/
6WXG\3KDVH 
,1'1XPEHU 
,QGLFDWLRQ 7UHDWPHQWRIK\SHUOLSLGHPLD
,QYHVWLJDWRUV $SSUR[LPDWHO\VLWHVL QWKH8QLWHG6WDWHV
6SRQVRU (VSHULRQ7KHUDSHXWLFV,QF
5DQFKHUR'ULYH6XLWH$QQ$UERU0,3KRQH)D[
6SRQVRU&RQWDFW
9HUVLRQ 'DWH
2ULJLQDO3URWRFRO 'HFHPEHU)LQDO
$PHQGPHQW 0DUFK
&RQILGHQWLDOLW\6WDWHPHQW
7+,6&21),'(17,$/,1)250$7,21,6$%287$1,19(67,*$7,21$/'58*3 529,'(')257+((;&/86,9(86(2),19(67,*$72562)
7+,6'58*$1',668%-(&7725(&$//$7$1<7,0( 7+(,1)250$7,21,17+,6'2&80(170$<127%(',6&/26('81/(6668& +
',6&/2685(,65(48,5('%<)('(5$/2567$7(/$:255(*8/$7,216 68%-(&7727+()25(*2,1* 7+,6,1)250$7,210$<%(
',6&/26('21/<727+26(3([ZIP_CODE],192/9(',17+(678'<:+2+$9( 1(('72.12: :,7+7+(2%/,*$7,2112772)857+(5
',66(0,1$7(7+,6,1)250$7,21 7+(6(5(675,&7,21621',6&/2685(:,//$33/<(48$//<72$//)8785 (25$/25:5,77(1
,1)250$7,21 6833/,('72<28%< (63(5,217+(5$3(87,&6 ,1&:+,&+,6'(6,*1$7('$6 Â³35,9,/(*(' Â´25Â³&21),'(17,$/ 
1&7QXPEHU1&7
7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW
IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOVJRY
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 2 of 101  2. SYNOPSIS  
Name [CONTACT_790]/Company : Esperion Therapeutics, Inc.  
Title of Study:  
A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic 
Acid 180 mg  + Ezetimibe 10  mg Fixed -Dose Combination Compared to Ezetimibe and Placebo in 
Subjects With Type  2 Diabetes  and Elevated LDL- Cholesterol  
Study  Number: 1002FDC-058  
Phase of Development: 2 
Clinical Sites: Approximately  [ADDRESS_364276] (IMP):  
Bempedoic Acid 180 mg  (BA)  + Ezetimibe  (EZE)  10 mg fixed -dose combination (FDC)  
EZE 10 mg 
Placebo (PBO)  
Primary Objectives:  
The Co-primary O bjective s are:  
â€¢ To assess the efficacy of FDC versus PBO on low-density-lipoprotein cholesterol (LDL -C) 
lowering in subjects  with type 2 diabetes (T2D) treated for 12 weeks; and  
â€¢ To assess the efficacy of FDC versus EZE on LDL -C lowering in subjects with T2D treated for 
12 weeks.  
Secondary Objectives:  
â€¢ To assess the efficacy of EZE versus PBO on LDL-C lowering in subjects with T2D treated for 
12 weeks;  
â€¢ To assess the efficacy of FDC versus PBO , FDC versus and EZE , and EZE versus PBO  on high-
sensitivity C -reactive protein (hs- CRP), non-high-density lipoprotein cholesterol ( non-HDL -C), 
total cholesterol (TC),  apolipoprotein B (apoB) , triglycerides (TG), and high -density lipoprotein 
cholesterol (HDL -C) in subjects with T2D treated for 12  weeks; 
â€¢ To assess the effect of FDC , EZE , and PBO on percent of subjects achieving LDL -C level 
<70 mg/dL ; 
â€¢ To assess the effect of FDC , EZE , and PBO on pe rcent of subjects achieving LDL -C reduction 
â‰¥50% ; and  
â€¢ To characterize the safety and tolerability of FDC , EZE , and PBO in subjects with T2D treated 
for 12  weeks. 
Exploratory Objectives:  
â€¢ To assess the effect of FDC versus PBO, FDC versus EZE, and EZE versus PBO on hemoglobin 
A1C (HbA 1C), fasting glucose,  homeostatic model 
assessment 
of insulin resistance (HOMA -IR) and , and 
2-hour postprandial glucose (PPG) in subjects with T2D treated for 12  weeks.  

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 3 of 101  Study Design:  
This is a Phase 2, randomized, double-blind, parallel group , multicenter study of FDC  versus EZE and 
PBO administered for 12 weeks in subjects with T2D and elevated LDL -C.  An overview of the study 
design is presented below.  
Overview of Study Design 
  
T2D = type 2 diabetes; HbA 1C = hemoglobin A 1C; LDL -C = low -density lipoprotein cholesterol; LMT  = lipid-
modifying therapy; BA = bempedoic aci d; EZE = ezetimibe; FDC = fixed -dose combination.  
 
Subjects with a history of T2D for at least 6  months will be screened for eligibility at an initial screening 
visit (Visit S1), which will be conducted approximately [ADDRESS_364277] an LDL- C level >70  mg/dL and who meet all other inclusion/exclusion criteria 
will be return for Visit S2 approximately 5 weeks prior to planned randomization into the study to washout of all LDL-C-lowering therapi[INVESTIGATOR_298520] -blind (subject) PBO.  Subjects will 
return to the study site approximately [ADDRESS_364278] an LDL -C level â‰¥100 mg/dL and who continue to meet the study inclusion/exclusion 
criteria  will be scheduled for their first treatment visit.  
Subjects will report to the study site for the first treatment visit (Visit  T1/Day  1) after a minimum 
10-hour fast.  Subjects who continue to meet the study inclusion/exclusion criteria will be randomized in 
a 1:1:1  ratio to receive either FDC (n  = 56), EZE (n  = 56), or PBO (n = 56) once daily  in the morning for 
12 weeks.  Randomized subjects will return for clinic visits at Week  4 (Visit T2) and Week  12 
(Visit T3/End of Study [EOS]). Subjects who withdraw from investigational medicinal product (IMP) 
treatment will be asked to continue to be followed for safety and efficacy using the protocol- specified 
visit schedule and procedures.  
Subjects will report to each of the study visits after a minimum [ADDRESS_364279] been completed.  All other doses 
of IMP will be self -admini stered by [CONTACT_748]; the last dose will be taken the day prior to the final 
clinical visit (Visit T3/EOS).   
Study Population:  
Approximately [ADDRESS_364280] 6  months and who meet 
the inclusion and exclusion criteria will be enrolled.  

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364281] satisfy all the following criteria  at V isit S1 (unless otherwise specified ) for enrollment in 
the study: 
1. The subject must be willing to provide written informed consent before any study- specific 
procedures are performed; 
2. The subject must be aged 18 -75 years or be of legal age of majority based on regional law, 
whichever is older;  
3. The subject must have a history of T2D for 6  months or greater; and must be currently taking 
stable diabetes medication for 3  months or greater with HbA 1C between 7% and 10% at Visit S1;  
4. The subject must have a fasting calculated LDL -C level >70  mg/dL at Visit  S1; 
5. The subject must have a fasting calculated LDL -C level between 100  and 220 mg/dL at Visit  S3 
after washout of all lipid -modifying therapy (LMT); 
6. The subject must clinically stable and suitable to undergo washout of all LDL -C-lowering drugs 
and nutritional supplements for 17 weeks (with potential for 1- week extension if repeat 
assessments described in the protocol are required) based on investigator assessment;  
7. The subject may be male or female.  Women must not be pregnant (or planning to become 
pregnant within [ADDRESS_364282] dose of IMP) or lactating and must be:  
a. Naturally postmenopausal, defined as â‰¥1  year without menses and either:  
i. â‰¥55 years old, or 
ii. <55 years old with a follicle -stimulating hormone (FSH) level â‰¥40.0 IU/L;  
b. Surgically sterile by [CONTACT_31658], bilateral oophorectomy, and/or tubal ligation; or 
c. Willing to use [ADDRESS_364283] agrees to follow the definition of true abstinence.  The minimal requirement for use of acceptable contraception is from the time the informed consent form (ICF) is signed, 
during the study period, and for at least [ADDRESS_364284] dose of IMP.  Acceptable 
methods of birth control include: 
i. placement of an intrauterine device (IUD) with or without hormones, 
ii. established use of oral, implanted, topi[INVESTIGATOR_2855], or injectable, or hormonal method of 
contraception associated with inhibition of ovulation, 
iii. barrier methods, including condom or occlusive cap with spermicidal foam or spermicidal jelly,  
iv. vasectomized male partner who is the sole partner for the subject, or  
v. true abstinence when this is in line with the preferred and usual lifestyle of the subject.  Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods), 
declaration of abstinence for the duration of a trial, and withdrawal are not acceptable 
methods of contraception. 
There are no protocol-specific birth control requirements for men who have partners that can become pregnant. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364285] Exclusion Criteria  
Subjects who meet any of the following criteria at Visit S1 (unless otherwise specified) will be excluded 
from the study: 
1. The subject has a body mass index (BMI) >40 kg/m2; 
2. The subject has a history of documented clinically significant cardiovascular disease including, 
but not limited to:  
a. myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary 
artery by[CONTACT_9292], stroke, transient ischemic attack, cerebrovascular event, symptomatic 
carotid artery disease, or symptomatic peripheral arterial disease;  
b. uncontrolled hypertension, defined as mean systolic blood pressure â‰¥160 mmHg and/or diastolic blood pressure â‰¥100 mmHg after sitting quietly for 5  minutes. 
Note: At the discretion of the investigator, a single repeat sitting systolic blood pressure a nd 
diastolic blood pressure may be obtained at another visit; the repeat values will be used to determine the subjectâ€™s eligibility for the study;  
c. an arrhythmia requiring medical intervention; 
d. abdominal or thoracic aortic aneurysm;  
e. [LOCATION_001] Heart Association (NYHA) Class  III and  IV heart failure;  
3. The subject has a fasting TG level >400  mg/dL at Visit S3;  
Note: At the discretion of the investigator, a repeat TG measurement may be obtained once, and 
the screening period will be extended for up to [ADDRESS_364286]â€™s eligibility for the study;  
4. The subject has a history of type 1 diabetes; 
5. The subject has uncontrolled hypothyroidism, including a value for thyroid-stimulating hormone 
(TSH) >1.5  Ã— the upper limit of no rmal (ULN);  
6. The subject has liver disease or dysfunction, including:  
a. positive serology for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus antibodies 
(HCV -AB) at Week  -1 (Visit  S2/Day -7), or  
b. serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value â‰¥2  Ã— ULN 
and/or serum total bilirubin (TB) value â‰¥2 Ã— ULN.  If the serum TB value is â‰¥1.2 Ã— ULN, a 
reflex indirect (unconjugated) bilirubin will be obtained and, if consistent with Gilbertâ€™s disease or if the subject has a his tory of Gilbertâ€™s disease, the subject may be enrolled in the 
study.  
Note: At the discretion of the investigator, a single repeat measurement of serum ALT, AST, and/or TB may be completed; the repeat value will be used to determine eligibility for the stu dy.  
If a test for HCV -AB is positive, but an optional reflexive test for hepatitis C virus (HCV) 
ribonucleic acid (RNA) is negative, the subject can be enrolled in the study;  
7. The subject has renal dysfunction or glomerulonephritis, including an estimated glomerular filtration rate (eGFR) <30  mL/min/1.73 m
2 (as determined by [CONTACT_6558] [MDRD] formula);  
Note: At the discretion of the investigator, a single repeat eGFR may be obtained; the repeat value will be used to determine eligibility for the study; 
8. The subject has gastrointestinal conditions or has undergone procedures (including weight loss surgery; eg, Lap -Band, gastric by[CONTACT_6476]) that may affect drug absorption;  
9. The subject has hematologic o r coagulation disorders or a hemoglobin (Hgb) level <10.0 g/dL;  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364287] had an active malignancy, including those requiring surgery, chemotherapy, and/or 
radiation, in the past 5 years.  Nonmetastatic basal or squamous cell carcinoma of the skin and 
cervical carcinoma in  situ are allowed;  
11. The subject has an unexplained (ie, not associated with recent trauma or physically strenuous activity) serum creatine kinase (CK) value >3  Ã— ULN at any time before randomization.  
Subjects with an explained elevation in serum CK must have single repeat serum CK value 
â‰¤3 Ã— ULN before randomization; 
12. The subject has a history of drug or alcohol abuse within the last 2 years or reports current consumption of >14 alcoholic drinks/week, uses any illicit drugs, or has a histo ry of 
amphetamine or derivatives abuse or cocaine abuse.  Subjects who are using amphetamine derivatives prescribed by [CONTACT_298540] a health care practitioner can be enrolled after evaluation by [CONTACT_093];  
13. The subject has donated blood, undergone multiple blood draws in a clinical study, experienced major trauma, received a blood transfusion, or undergone surgery, with or without blood loss, 
within 30  days before randomization;  
14. The subject has used any experimental or investigational  drugs within 30  days before screening 
and throughout the trial; 
15. The subject has previously participated in a clinical study of BA ; 
16. The subject has experienced history of intolerance to EZE; 
17. The subject has used prohibited drugs and/or nutritional suppleme nts within 5  weeks prior to 
Visit  T1 (unless otherwise specified) or plans to use any of the prohibited drugs and/or 
nutritional supplements during the study, including but not limited to:  
a. Statins;  
b. Fibrates (including fenofibrate);  
c. Niacin and derivatives; 
d. Bile acid sequestants;  
e. Ezetimibe (study -provided is allowed);  
f. Apheresis;  
g. Mipomersen or lomitapi[INVESTIGATOR_5328] (6 months prior to Visit S1);  
h. Proprotein convertase subtilisin/kexin type  9 (PCSK9) inhibitors (4 months prior to Visit  S1, 
except PCSK9 small interfering  RNA (siRNA), which are prohibited if used at any time in 
the past);  
i. Cholesteryl ester transfer protein (CETP) inhibitors (12  months prior to Visit  S1);  
j. Red yeast rice extract-containing products;  
k. Omega 3 fatty acids and derivatives such as Lovaza
Â® and ov er-the-counter ( OTC ) fish oil;  
l. Systemic corticosteroids (within 5  weeks prior to Visit  T1); topi[INVESTIGATOR_298521];  
m. The following ther api[INVESTIGATOR_298522] T2D:  rapid -acting and short- acting insulins 
including Lispro (HumaLogÂ®), Aspart (NovalogÂ®), Glulisine (AdipraÂ®), Novolin R/ Novolin 
Regular, Humulin R/Humulin Regular (except when used for basal delivery by [CONTACT_298541]); injectable GLP -1 agonists such as Exenatide (By[CONTACT_28557], By[CONTACT_28556]),  liraglutide 
(VictozaÂ®), albiglutide (TanzeumÂ®) and dulaglutide (TrulicityÂ®); injectable synthetic forms 
of amylin such as Pramlintide (Symlin); and insulin glargine/lexisenatide (SoliquaÂ®) (within 
3 months prior to Visit  T1). 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364288] has planned initiation of or dosing changes in the fol lowing allowed drugs before or 
during the study: 
a. Oral diabetes medications (within 3  months prior to Visit  T1);  
b. Intermediate- acting and long-acting insulin and insulin analogs when used for basal delivery 
of insulin including NPH, NovoLIN N, HumuLIN N, Gl argine (Lantus), Determir (Levemir), 
NovoLIN 70/30, HumuLIN 70/30, NovoLog Mix 70/30 or HumuLOG Mix 70/30 (within 
3 months prior to Visit  T1); 
c. Rapid -acting and short -acting insulins only when used for basal infusion pump delivery (no 
bolus delivery allowed) including Lispro (HumaLogÂ®), Aspart (NovalogÂ®), Glulisine 
(AdipraÂ®), Novolin R/Novolin Regular, Humulin R/Humulin Regular (within 3 months prior 
to Visit  T1); 
d. Intermediate- acting and long-acting insulin and insulin analogs when used for basal delivery 
of insulin including NPH, NovoLIN N, HumuLIN N, Glargine (Lantus), Determir (Levemir), NovoLIN 70/30, HumuLIN 70/30, NovoLog Mix 70/30 or HumuLOG Mix 70/30 (within 
3 months prior to Visit  T1); 
e. Obesity medication (within 3  months prior to Visit  T1); 
f. Hormone r eplacement (within 5  weeks prior to Visit T1); or  
g. Thyroid replacement (within 5 weeks prior to  Visit  T1). 
19. The subject has a medical or situational (ie, geographical) finding that, in the investigatorâ€™s opi[INVESTIGATOR_1649], may compromise the subjectâ€™s safety or abilit y to complete the study;  
20. The subject is an employee or contractor of the facility that is conducting the study or is a family 
member of the principal investigator, co-investigator, or any sponsor personnel. 
IMP Dosage and Mode of Administration:  
Bempedoic acid 180 mg  + EZE [ADDRESS_364289]:  
All other background drugs including diabetes medications will be administered as prescribed by a physician. 
Study Duration:  
The expected study duration is approximately 126 days, including an approximate 42- day screening 
period (Visit S1/Day -42, followed by a 5- week single -blind PBO run-in / LMT washout period from 
Day -35 to Day  -1), an 84- day treatment period  beginning at Visit T1/Day 1, and an EOS visit 
(Visit T3/Day  85).  
Criteria for evaluation:  
Lipid, Cardiometabolic and Glycemic Assessments:  
â€¢ Calculated fasting serum lipi[INVESTIGATOR_298523] -C, non- HDL -C, TC, and apoB, TG, and HDL-C;  
âˆ’ If TG exceeds 400  mg/dL (4.5 mmol/L) or LDL- C is <50  mg/dL (1.3 mmol/L), direct 
measure of LDL -C will be conducted and will be used in the analyses.  
â€¢ Serum hs- CRP ; 
â€¢ Blood HbA 1C; 
â€¢ Plasma glucose (fasting and [ADDRESS_364290] prandial); 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 8 of 101  Safety Assessments:  
Treatment -emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of 
special interest (AESIs) will be reported by [CONTACT_1570]. Other safety assessments will include 
clinical safety laboratories (including hematology, blood chemistry, and urinal ysis), physical examination 
(PE) fin dings and vital signs . 
 
Clinical Laboratory Assessments:  
â€¢ Hematology:  Hematocrit (Hct), Hgb, mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelet count, red blood 
cell (RBC) count, white blood cell (WBC) count with differential (absolute values only). 
â€¢ Urinalysis (Dipstick):  Clarity, bilirubin, color, glucose, ketones, leukocyte esterase, nitrite, 
occult blood, pH, protein, specific gravity, urobilinogen.  
â€¢ Urinalysis (Microscopic):  Obtain centrally only if positive urine dipstick; bacteria, casts, 
crystals, epi[INVESTIGATOR_1663], RBC, and WBC.  
â€¢ Serum Chemistry (fasting):  Albumin (ALB), alkaline phosphatase (ALK- P), ALT (or serum 
glutamic pyruvic transaminase [SGPT]), AST (or serum glutamic oxaloacetic transaminase [SGOT]), blood urea nitrogen (BUN), calcium (Ca), carbon dioxide (CO
2), chloride (Cl), 
creatinine, CK , lactate dehydrogenase (LDH), phosphorus, potassium (K), sodium (Na), total 
and direct bilirubin, total protein, uric acid. 
 
Other Assessments: 
HBsAg, HCV, serum (Visit S1)  and urine (Visit  T1) pregnancy test (only for females who are of 
childbearing potential), FSH (only for women <55 years old  and â‰¥1 year without menses), TSH.   Reserve 
blood samples (serum and plasma) for potential future measurement of potential biomarkers (Visit  T1, 
T3).  
Statistical Methods  
Sample Size   
The sample size of approximately [ADDRESS_364291] s per treatment arm (1:1:1) in this study (168 subjects total) 
is selected to provide adequate power for each of the co -primary endpoint as well as the co -primary 
endpoint family as a whole. 

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364292] OF ABBREVIATION S AND DEFINITIONS OF  TERMS .............................15  
5. INTRODUCTION  ......................................................................................................19  
5.1. Lipid -Regulating Drugs and Cardiovascular Disease .................................................19  
5.1.1.  Overview of Bempedoic Acid  ....................................................................................20  
5.1.2.  Mechanism of Action  .................................................................................................20  
5.1.3.  Nonclinical Experience  ...............................................................................................20  
5.1.4.  Previous Human Experience .......................................................................................21  
5.2. Risk-Benefit Assessment  ............................................................................................22  
6. TRIAL OBJECTIVES AND PURPOSE  ....................................................................23  
6.1. Primary Objectives  .....................................................................................................23  
6.2. Secondary Objectives  .................................................................................................23  
6.3. Exploratory Objectives ...............................................................................................23  
6.4. Study Endpoints  ..........................................................................................................23  
6.4.1.  Primary Endpoint ........................................................................................................23  
6.4.2.  Secondary Endpoints ..................................................................................................23  
6.4.3.  Exploratory Endpoints ................................................................................................24  
6.4.4.  Safety Endpoints  .........................................................................................................24  
7. INVESTIGATIONAL PLAN  .....................................................................................25  
7.1. Overall Study Design  ..................................................................................................25  
7.2. Study Hypothesis  ........................................................................................................26  
7.3. Rationale for Dose Selection  ......................................................................................26  
7.4. Study Duration  ............................................................................................................26  
7.5. Number of Subjects ....................................................................................................26  
7.6. Replacement of Subjects  .............................................................................................26  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364293] Exclusion Criteria  ..........................................................................................28  
8.3. Lifestyle and Dietary Guidelines  ................................................................................31  
8.4. Investigator/Sponsor Suspension or Termination of Subject Enrollment ..................[ADDRESS_364294] ......................................................32  
9.2.1.  Bempedoic Acid 180 mg  + Ezetimibe [ADDRESS_364295] Identification Numbers  ..................................................................................41  
11.3.  Rescreening  .................................................................................................................41  
11.4.  Procedures and Schedule of Assessments ..................................................................41  
11.5.  General Visit Guidelines  .............................................................................................41  
11.6.  Screening Period  .........................................................................................................42  
11.6.1.  Screening Period Visit 1 (Visit S1/Day -42 Â± 7) ........................................................42  
11.6.2.  Screening Period Visit 2 (Visit S2/Day -35 Â± 3) ........................................................43  
11.6.3.  Screening Period Visit 3 (Visit S3/Day -7 Â± 3) ..........................................................43  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 11 of 101  11.7.  Treatment Period  ........................................................................................................44  
11.7.1.  Treatment Period Visit 1 (Visit T1/Day 1)  .................................................................44  
11.7.2.  Treatment Period Visit 2 (Visit T2/Day 28 Â± 3)  .........................................................45  
11.7.3.  Treatment Visit 3 (Visit T3/EOS/Day 85 Â± 3) ............................................................[ADDRESS_364296] Withdrawal Criteria  .......................................................................................46  
11.8.1.  Early Withdrawal from Study  .....................................................................................46  
11.8.2.  Procedures for Early Withdrawal  ...............................................................................47  
12. ASSESSMENT OF PHARMACODYNAMICS  ........................................................48  
12.1.  Pharmacodynamic Assessments  .................................................................................48  
12.1.1.  Sample Collection, Storage, and Shippi[INVESTIGATOR_007] .................................................................48  
12.1.2.  Sample Collection, Storage, and Shippi[INVESTIGATOR_007] .................................................................48  
12.1.3.  Two-hour Postprandial Glucose (PPG) Assessment ..................................................48  
12.1.4.  HOMA- IR and ...........................................................................48  
12.1.5.  Exploratory Biomarker Measurement ........................................................................49  
12.1.6.  Clinical Laboratory Parameters (Basic Fasting Lipi[INVESTIGATOR_805], Special Lipi[INVESTIGATOR_298524])  ......................................................................................................49  
13. ASSESSMENT OF SAFETY  .....................................................................................50  
13.1.  Demographics and Medical History  ...........................................................................50  
13.2.  Vital Signs  ..................................................................................................................50  
13.3.  Weight, Height, and Body Mass Index  .......................................................................50  
13.4.  Physical Examination  .................................................................................................50  
13.5.  12-Lead Electrocardiograms  .......................................................................................51  
13.6.  Clinical Laboratory Tests  ...........................................................................................51  
13.6.1.  Clinical Safety Laboratory Parameters  .......................................................................51  
13.6.2.  Sample Collection, Storage, and Shippi[INVESTIGATOR_007] .................................................................53  
13.6.3.  General Monitoring and Management of Abnormal Clinical Laboratory Values  .........................................................................................................................53
 
[IP_ADDRESS].  Monitoring and Management of Elevated Liver Function Tests ................................54  
[IP_ADDRESS].  Monitoring and Management of Elevated Serum Creatinine Levels .........................55  
[IP_ADDRESS].  Monitoring and Management of Changes in Hemoglobin Levels  ..............................55  
[IP_ADDRESS].  Monitoring and Management of Elevated Creatine Kinase Levels ............................56  
[IP_ADDRESS].  Monitoring and Management of Potential Hypoglycemia and Metabolic Acidosis ......................................................................................................................56
 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 12 of 101  13.6.4.  Total Blood Volume ...................................................................................................57  
13.7.  Adverse and Serious Adverse Events .........................................................................57  
13.7.1.  Adverse Events  ...........................................................................................................57  
[IP_ADDRESS].  Definition of Adverse Events .....................................................................................57  
[IP_ADDRESS].  Adverse Drug Reaction  ...............................................................................................57  
[IP_ADDRESS].  Reporting of Adverse Events ......................................................................................58  
[IP_ADDRESS].  Severity  .......................................................................................................................59  
[IP_ADDRESS].  Relationship  ................................................................................................................59  
[IP_ADDRESS].  Monitoring and Follow-up of Adverse Events ...........................................................60  
[IP_ADDRESS].  Treatment -Emergent Adverse Events  .........................................................................60  
13.7.2.  Serious Adverse Events ..............................................................................................60  
[IP_ADDRESS].  Definition of Serious Adverse Event ..........................................................................60  
[IP_ADDRESS].  Definition of Adverse Events or Outcomes Not Qualifying as Serious 
Adverse Events  ...........................................................................................................61  
[IP_ADDRESS].  Clinical Laboratory Assessments as Adverse Events and Serious Adverse Events .........................................................................................................................61
 
[IP_ADDRESS].  Reporting Serious Adverse Events .............................................................................61  
[IP_ADDRESS].  Reporting of Serious Adverse Events to Regulatory Authorities ...............................62  
[IP_ADDRESS].  Reporting of Subject Death ........................................................................................62  
[IP_ADDRESS].  Reports of Pregnancy ..................................................................................................[ADDRESS_364297] ACCESS TO SOU RCE DATA/DOCUMENTS .........................................70  
15.1.  Study Monitoring ........................................................................................................70  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364298]/Independent Ethics Committee Approval ......................[ADDRESS_364299] OF REFERENCES  ............................................................................................79  
22. APPENDICES  ............................................................................................................81  
APPENDIX 1.  SCHEDULE OF ASSESSME NTS  ....................................................................82  
APPENDIX 2.  SPONSOR SIGNATURE  ..................................................................................85  
APPENDIX 3.  INVESTIGATOR SIGNATURE  .......................................................................86  
APPENDIX 4.  SUMMARY OF CHANGES AMENDMENT 1  ...............................................87  
 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364300] OF TABLES  
Table 1:  Description of Bempedoic Acid + Ezetimibe FDC Tablets, Ezetimibe 
Tablets and Placebo Tablets  .......................................................................................33  
Table 2:  Clinical Laboratory Parameters (Basic Fasting Lip ids, Special Lipi[INVESTIGATOR_298524])  ......................................................................................................49  
Table 3:  Clinical Safety Laboratory Evaluations  ......................................................................[ADDRESS_364301] OF FIGURES  
Figure  1: Overview of Study Design ..........................................................................................25  
 
 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364302] research organization 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364303] Term  Explanation 
CTT  Cholesterol Treatment Trialists  
CYP  cytochrome P450 
ECG  electrocardiogram  
eCRF  electronic case report form  
EENT eyes, ears, nose, and throat  
eGFR  estimated glomerular filtration rate  
EOS  end of study  
ESP15228 primary metabolite of bempedoic acid (ETC-1002) 
ETC -[ADDRESS_364304](s)  

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364305]  
IUD intrauterine device  
IWRS  interactive web response system  
K potassium 
Kg/m2 Kilograms per square meters 
LDH lactate dehydrogenase 
LDL -C low-density lipoprotein cholesterol  
LDLR  low-density lipoprotein receptor  
LFT liver function test  
LMT lipid-modifying therapy 
LOCF  last observation carried forward  
LSM  least squares mean  
MCH mean corpuscular hemoglobin 
MCHC  mean corpuscular hemoglobin concentration 
MCV mean corpuscular volume 
MDRD Modification of Diet in Renal Disease  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance imaging  
N/A not available  
Na sodium 
N/D not done 
NOAEL  no-observed -adverse- effect level  
Non-HDL -C non-high-density lipoprotein cholesterol 
NYHA  [LOCATION_001] Heart Association  
OTC  over-the-counter 
PBO placebo 
PCSK9  proprotein convertase subtilisin/kexin type 9  
PE physical examination 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364306] identification number  
S[LOCATION_003]Rs  suspected unexpected serious adverse reactions  
tÂ½  terminal elimination half -life 
T2D type 2 diabetes 
TB total bilirubin  
TC total cholesterol  
TEAE  treatment -emergent adverse event  
TG triglycerides  
TQT  thorough QT/QTc 
TSH  thyroid-stimulating hormone 
ULN upper limit of normal 
US [LOCATION_002]  
WBC white blood cell  
 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 19 of 101  5. INTRODUCTION 
5.1. Lipid -Regulating Drugs and Cardiovascular Disease  
Bempedoic acid ( BA; ETC -1002) is an inhibitor of adenosine triphosphate- citrate lyase (ACL) 
(adenosine triphosphate [ATP] citrate lyase), an enzyme upstream of 3-hydroxy-3- methylglutaryl 
coenzyme A (HMG -CoA) reductase in the cholesterol biosynthesis pathwa y.  It is an oral, 
first-in-class small molecule designed to lower  low-density lipoprotein cholesterol ( LDL-C) 
levels in patients with high cardiovascular risk who are unable to meet their treatment goals with 
currently available lipid -lowering therapi[INVESTIGATOR_014].  Bempedoic acid is being evaluated as an adjunct to 
diet alone or in combination with other lipid- lowering therapi[INVESTIGATOR_298525]/or clinical atherosclerotic cardiovascular disease 
who are on maximally tolerated statin therapy and who require additional lowering of LDL- C or 
who are unable to tolerate effective doses of currently available statin formulations.  
Elevated  LDL-C level  is a major modifiable risk factor for the development of atherosclerosis 
and atherosclerotic cardiovascular  diseases .1  Despi[INVESTIGATOR_298526], cardiovascular  disease is the number 1 cause of death globally.2  An 
estimated 17.7 million people died from cardiovascular  diseases in 2015, representing 31% of all 
deaths worldwide.  Of these deaths, an estimated 7.4 million wer e due to coronary heart di sease,  
and 6.7 million were due to stroke.2  Cardiovascular disease remains the leading cause of death 
among Americans, Europeans, and around the world.  The Global Burden of Disease study estimated that 29.6% of all deaths (
approximately 15.6 million deaths) were caused by 
[CONTACT_298542] 2010, more than all communicable, maternal, neonatal, and nutritional 
disorders combined, and double the number of deaths caused by [CONTACT_282628].3  Based on 2011 death 
rate data, more than 2150 Americans die from cardiovascular  diseases daily, for an average of 
1 death every 40 seconds.  Approximately 155,000 Americans who die from cardiovascular  
disease are younger than 65 years of age.  In 2011, 34% of deaths due to cardiovascular  disease 
occurred prior to the age of 75 years, less than the current 78.7- year average life expectancy .4 
LDL-C is largely accepted as a valid surrogate endpoint of cardiovascular  events by [CONTACT_298543].5  Long -term elevations in LDL -C lead to progressive accumulation of 
atherosclerotic lesions in the walls of arteries that require long -term management.  While 
lifestyle changes are the primary intervention, these measures rarely decrease plasma LDL -C by 
>15%.  Evidence supporting LDL- C as a therapeutic target and surrogate for cardiovascular  
outcomes comes from interventional studies with LDL-C- lowering therapi[INVESTIGATOR_014], epi[INVESTIGATOR_34207], and genetic variants (both gain of function and loss of function).  Large randomized 
clinical studies aimed at lowering LDL -C show a consistent log- linear relationship between 
LDL-C reduction and cardiovascular  risk reduction, independent of the way LDL- C lowering 
was achieved based on mechanism of action .6-9  A published patient -level meta -analysis , which 
includes 26 trials and more than 160,000 participants, showed a consistent relationship between 
LDL-C reduction and cardiovascular  outcomes.7  This analysis showed that a 1 mmol/L 
reduction in LDL- C was associated with a 22%  reduction in the 5- year incidence of major 
coronary events, revascularizations, and ischemic strokes.  Intensive statin therapy relative to 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 20 of 101  low/moderate intensity statin treatment produces greater benefit in patients at high 
cardiovascular  risk.10 
Unfortunately, some patients with elevated LDL-C are unable to take high intensity statins due to 
dosing limits based on comorbidities, contraindications, and/or tolerance.11  Nonstatin  therapi[INVESTIGATOR_298527]- IT 
trial, which added ezetimibe (EZE)  to statin therapy .12  Bempedoic acid and EZE are oral 
therapi[INVESTIGATOR_298528]-C via up-regulation of LDL 
receptors.  Coadministration  of BA and EZE may, therefore, result in further reductions in 
LDL-C than can be obtained with either agent alone, thereby [CONTACT_1541] a therapeutic benefit to 
patients who do not achieve optimal lowering of LDL- C with either treatment alone.  
The availabilit y of a fixed -dose combination (FDC) tablet of BA  180 mg and EZE  10 mg (the 
recommended dose of each agent) would provide convenience to patients over coadministration of individual tablets, thereby [CONTACT_298544].  This 12- week study will e valuate 
the efficacy and safety of FDC compared to EZE 10 mg or placebo (PBO) in subjects with type 2 
diabetes (T2D) and elevated LDL -C levels.   
5.1.1. Overview of Bempedoic Acid  
A complete summary of the available and nonclinical and clinical experience with BA is 
provided in the Investigator â€™s Brochure.
[ADDRESS_364307].  Bempedoic acid is a prodrug that requires 
activation in liver to ETC -1002- coenzyme A (ETC -1002-CoA), which mediates c ompetitive 
inhibition of ACL.  Inhibition of ACL by [CONTACT_76753]-1002- CoA decreases cholesterol synthesis in the 
liver leading to increased low -density lipoprotein receptor (LDLR) expression and LDL particle 
clearance from the blood.  Therefore, inhibition of ACL b y ETC -1002- CoA decreases LDL -C 
via the same pathway as HMG -CoA reductase inhibition by [CONTACT_101818].  
An important differentiating feature of BA is that, unlike statins, it does not inhibit cholesterol 
synthesis in skeletal muscle.  The enzyme required to convert BA to ETC -1002-CoA is not 
present in skeletal muscle.   Therefore, BA is not anticipated to mediate the adverse effects 
associated with inhibition of biological intermediates within the cholesterol biosynthesis pathway in skel etal muscle; however, the safety of BA and its metabolites regarding human skeletal 
muscle is not yet established.  
5.1.3. Nonclinical Experience 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 21 of 101  5.1.4. Pre
vious Human Experience  

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364308] s with elev ated LDL -C levels who are on low or less- than-low doses of statins 
(Protocol 1002-048) has not identified any new safety concerns associated with coadministration 
of BA and EZE . 
Information on the potential risks of BA  is provided in the Investigatorâ€™s Brochure for BA.13  
Information on the potential risks of EZE is provided in the prescribing information for EZE 
tablets.14  

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 23 of 101  6. TRIAL OBJECTIVES AND  PURPOSE  
6.1. Primary Objectives 
â€¢ To assess the  efficacy of FDC versus PBO on LDL- C lowering  in subjects with T2D 
treated for 12 weeks; and   
â€¢ To assess the  efficacy of FDC versus EZE on LDL- C lowering  in subjects with T2D 
treated for 12 weeks . 
6.2. Secondary O bjectives  
â€¢ To assess the  efficacy of EZE versus PBO on  LDL- C lowering  in subjects with T2D 
treated for 12 weeks ; 
â€¢ To assess the efficacy of FDC versus PBO , FDC versus EZE , and EZE versus PBO 
on high -sensitivity C -reactive protein (hs-CRP), non- HDL -C, total cholesterol (TC),  
apolipoprotein B (apoB) , TG, and HDL-C in subjects with T2D treated for 12  weeks ; 
â€¢ To assess the effect of FDC, EZE , and PBO on percent of subjects achieving LDL- C 
level <70  mg/dL;  
â€¢ To assess the effect of  FDC , EZE , and PBO on percent of subjects achieving LDL- C 
reduction â‰¥50%; and 
â€¢ To characterize the safety and tolerability of FDC , EZE , and PBO in subjects with 
T2D treated for 12  weeks.  
6.3. Exploratory Objectives  
â€¢ To assess the effect of FDC versus PBO and EZE on hemoglobin A 1C (HbA 1C), 
fasting glucose,  homeostatic model 
assessme nt 
of insulin sensitivity (HOMA -IR) and
 and 2-hour postprandial glucose (PPG) in subjects with T2D  treated for 
12 weeks . 
6.4. Study Endpoints  
6.4.1. Primary  Endpoint  
â€¢ Percent change from baseline to Week  12/End of Study ( EOS ) in LDL- C. 
6.4.2. Secondary  Endpoints  
â€¢ Percent change from baseline to Week  12 in hs- CRP , non- HDL -C, TC, apoB, TG, 
and HDL -C; 
â€¢ Percent of subject s with  LDL- C <70  mg/dL at Week  12; 
â€¢ Percent of subject s with LDL -C reduction â‰¥50% from baseline to Week 12. 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 24 of 101  6.4.3. Exploratory Endpoints  
â€¢ Percent change from baseline at Wee
k 12 in parameters below: 
âˆ’ HbA 1C; 
âˆ’ Plasma glucose (fasting and 2 -hour PPG ); 
âˆ’ HOMA-IR index; 
6.4.4. Saf
ety Endpoints  
â€¢ TEAEs ; 
â€¢ SAEs ; 
â€¢ Clinical safety laboratories (hematology, clinical chemistry, and urinalysis) ; 
â€¢ Vital signs ; 
â€¢ PEs. 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 25 of 101  7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design  
This is a Phase  2, randomized, double-blind, parallel -group, multicenter study of BA 180 mg and 
EZE 10 mg  FDC  versus PBO and EZE 10 mg administered for 12 weeks  in subjects with T2D 
and elevated LDL -C.  An overview of the study design is presented in Figure  1. 
Figure  1: Overview of Study Design 
 
T2D= type 2 diabetes; HbA1c = hemoglobin A1c; LDL -C = low -density lipoprotein cholesterol; LMT = lipid -
modifying therapy; BA = bempedoic acid; EZE = ezetimibe; FDC = fixed dose combination.  
Subjects with a history of T2D for at least 6  months will be screened for eligibility at an initial 
screening visit  (Visit S1), which will be conducted approximately [ADDRESS_364309] an LDL- C level >70 mg/dL and who meet all 
other inclusion/exclusion criteria will be return for Visit S2 approximately 5 weeks prior to 
planned randomization into the study to washout of all LDL-C- lowering therapi[INVESTIGATOR_298529] -blind (subject) PBO .  Subjects will return to the study site approximately [ADDRESS_364310] an LDL- C level 
â‰¥100 mg/dL and who continue to meet the study inclusion/exclusion criteria will be scheduled 
for their first treatment visit. 
Subjects will report to the study site for the first treatment visit (Visit T1/Day  1) after a minimum 
10-hour fast.  Subjects who continue to meet the study inclusion/exclusion criteria will be randomized in a 1:1:1  ratio to receive either FDC  (n = 56), EZE (n = 56), or PBO (n  = 56) once 
daily for 12 weeks .  Randomized subjects will return for clinic visits at Week  4 (Visit T2) and 
Week  12 (Visit T3/EOS).  Subjects  who withdraw from IMP treatment will be asked to continue 
to be followed for safety and efficacy using the protocol- specified visit schedule and procedures.   
Subjects  will be dispensed IMP at Visit T1 /Day [ADDRESS_364311] and without having 
taken their dose of IMP.  Study site personnel will administer the IMP on these days after blood 

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364312] been completed.  
All other doses of IMP will be self -administered by [CONTACT_748]; the last dose will be taken the 
day prior to the final clinical visit (Visit T3/EOS) .   
7.2. Study Hypothesis  
The clinical  hypothesis for this study is that FDC  therapy with BA180 mg, EZE 10 mg will 
significantly reduce LDL -C in subjects with T2D and elevated LDL -C treated daily for 12 weeks  
versus EZE 10  mg and versus PBO . 
7.3. Rationale for Dose Selection  
The daily dose of BA (180 mg) taken  as an individual tablet or in combination with EZE in the 
FDC tablet represents the dose that is being evaluated in Phase [ADDRESS_364313] s with hypercholesterolemia.  The daily dose of EZE (10 mg) 
taken  as an individual tablet or in combination with BA in the FDC tablets represents the 
recommended therapeutic dose for this drug.  
7.4. Study Duration  
The expected study duration is approximately 126 days, including an approximate 42- day 
screening period (Visit  S1/Day  -42, followed by a 5- week single -blind PBO  run-in/lipid-
modifying therapy ( LMT ) washout period from Day -35 to Day  -1), an 84- day treatment period  
beginning at Visit T1/Day  1, and an EOS visit (Visit T3/Day  85). 
7.5. Number of Subjects 
Approximately [ADDRESS_364314] 6  months and 
who meet the inclusion and exclusion crit eria will be enrolled  and randomized in a 1:1:1  ratio to 
receive FDC (n  = 56) or EZE (n  = 56) or PBO (n  = 56). 
7.6. Replacement of Subjects  
Subjects who are withdrawn from the study for any reason may be replaced at the discretion of 
the sponsor. 
7.7. Number of Clinical Sites  
Approximately 45 clinical sites  in the [LOCATION_002] ( US) will participate in this  study.  
Additional sites may be invited to participate to ensure study timelines are met.  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364315] satisfy all the following criteria at Visit S1 (unless otherwise specified) for 
enrollment in the study:  
1. The subject must be willing to provide written informed consent before any study 
specific procedures are performed;  
2. The subject must be aged  18-75 years or be of legal age of majority based on regional 
law, whichever is older;  
3. The subject must have a history of T2D for 6  months or greater; and must be currently 
taking s table diabetes medication for 3  months or greater with HbA 1C between 7% and  
10% at Visit S1; 
4. The subject mus t have a fasting calculated LDL -C level >70 mg/dL at Visit S1; 
5. The subject must have a fasting calculated LDL -C level between 100 and 220 mg/dL at 
Visit S3 after washout of all LMT; 
6. The subject must clinically stable and su itable to undergo washout of all LDL-C- lowering 
drugs and nutritional supplements for 17 weeks (with potential for 1- week extension if 
repeat assessments described in the protocol are required) based on investigator assessment;  
7. The subject may be male or f emale.  Women must not be pregnant (or planning to 
become pregnant within [ADDRESS_364316] dose of IMP) or lactating and must be: 
a. Naturally postmenopausal, defined as â‰¥1 year without menses and either:  
i. â‰¥55 years old, or 
ii. <55 years old with a follicle -stimulating hormone (FSH) level â‰¥40.0 IU/L; 
b. Surgically sterile by [CONTACT_31658], bilateral oophorectomy, and/or tubal ligation; or 
c. Willing to use [ADDRESS_364317] agrees to follow the definition of true abstinence.  The minimal 
requirement for use of acceptable contraception is from the time the informed consent form (ICF) is signed, during the study period, and for at least [ADDRESS_364318] dose of IMP.  Acceptable methods of birth control include: 
i. placement of an intrauterine device (IUD) with or without hormones, 
ii. established use of oral, implanted, topi[INVESTIGATOR_2855], or injectable, or hormonal method of 
contraception associated with inhibition of ovulation, 
iii. barrier methods, including condom or occlusive cap with spermicidal foam or 
spermicidal jelly,  
iv. vasectomized male partner who is the sole partner for the subject, or 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364319].  Periodic abstinence (eg, calendar, ovulation, symptothermal, post 
ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. 
There are no protocol-specific birth control requirements for men who have partners that can become pregnant.  
8.2. Subject  Exclusion Criteria 
Subjects who meet any of the following criteria at Visit S1 (unless otherwise specified) will be excluded from the study: 
1. The subject has a body mass index (BMI) >40 kg/m2; 
2. The subject has a history of documented clinically significant cardiovascular disease including, but not limited to: 
a. myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, 
coronary artery by[CONTACT_9292], stroke, transient ischemic attack, cerebrovascular event, 
symptomatic carotid artery disease, or symptomatic peripheral arterial disease ; 
b. uncontrolled hypertension, defined as mean systolic blood pressure â‰¥160 mmHg and/or diastolic blood pressure â‰¥100 mmHg after sitting quietly for 5  minute s; 
Note:   At the discretion of the investigator, a single repeat sitting systolic blood pressure and 
diastolic blood pressure may be obtained at another visit; the repeat values will be used to 
determine the subjectâ€™s eligibility for the study ; 
c. an arrhythm ia requiring medical intervention ; 
d. abdominal or thoracic aortic aneurysm ; 
e. [LOCATION_001]  Heart Association (NYHA) Class  III and  IV heart failure;  
3. The subject has a fasting TG level >400  mg/dL at Visit S3; 
Note: At the discretion of the investigator, a repeat TG measurement may be obtained once, and the screening period will be extended for up to [ADDRESS_364320]â€™s eligibility for the study;  
4. The subject has a history of type 1 diabetes;  
5. The subject has uncontrolled hypothyroidism, including a value for thyroid- stimulating 
hormone (TSH) >1.5 Ã— the upper limit of normal (ULN); 
6. The subject has liver disease or dysfunction, including:  
a. positive serology for hepatitis  B surface antigen (HBsAg) and/or hepatitis  C vi rus 
antib odies (HCV- AB) at Week  -1 (Visit S2/Day  7), or  
b. serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value 
â‰¥2 Ã— ULN and/or serum total bilirubin (TB) value â‰¥2 Ã— ULN.  If the serum TB value 
is â‰¥1.2 Ã— ULN, a reflex indirect (unconjugated)  bilirubin will be obtained and, if 
consistent with Gilbertâ€™s disease or if the subject has a history of Gilbertâ€™s disease, the subject may be enrolled in the study.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 29 of 101  Note:   At the discretion of the investigator, a single repeat measurement of serum ALT, AST, 
and/or TB may be completed; the repeat value will be used to determine eligibility for the 
study.  If a test fo r HCV -AB is positive, but an optional reflexive test for hepatitis  C virus 
(HCV) ribonucleic acid (RNA) is negative, the subject can be enrolled in the study;  
7. The subject has renal dysfunction or glomerulonephritis, including an estimated glomerular filtration rate (eGFR) <30  mL/min/1.73 m
2 (as determined by [CONTACT_298545] [MDRD] formula); 
Note:  At the discretion of the investigator, a single repeat eGFR may be obtained; the repeat 
value will be used to determine eligibility for the study;  
8. The subject has gastrointestinal conditions or has undergone procedures (including 
weight loss surgery; eg, Lap- Band, gastric by[CONTACT_6476]) that may affect drug absorption;  
9. The subject has hematologic or coagulation disorders or a hemoglobin (Hgb) level 
<10.0 g/dL;  
10. The subject had an active malignancy, including those requiring surgery, chemotherapy, and/or radiation, in the past 5 years.  Nonmetastatic basal or squamous cell carcinoma of 
the skin and cervical carcinoma in situ are allowed;  
11. The subject has an unexplained (ie, not associa ted with recent trauma or physically 
strenuous activity) serum creatine kinase (CK) value >3  Ã— ULN at any time before 
randomization.  Subjects with an explained elevation in serum CK must have single 
repeat serum CK value â‰¤3 Ã— ULN before randomization; 
12. The subject has a history of drug or alcohol abuse within the last 2 years or reports 
current consumption of >14 alcoholic drinks/week, uses any illicit drugs, or has a history of amphetamine or derivatives abuse or cocaine abuse.  Subjects who are using 
amphetamine derivatives prescribed by [CONTACT_298540] a health care practitioner can be enrolled after evaluation by [CONTACT_093];  
13. The subject has donated blood, undergone multiple blood draws in a clinical study, experienced major trauma, received a blood transfusion, or undergone surgery, with or without blood loss, within 30 days before randomization; 
14. The subject has used any experimental or investigational drugs within 30 days before screening and throughout the trial; 
15. The subject has prev iously participated in a clinical study of BA; 
16. The subject has experienced history of intolerance to EZE; 
17. The subject has used prohibited drugs and/or nutritional supplements within 5 weeks prior to Visit T1 (unless otherwise specified) or plans to use any of the prohibited drugs 
and/or nutritional supplements during the study, including but not limited to:  
a. Statins;  
b. Fibrates (including fenofibrate);  
c. Niacin and derivatives; 
d. Bile acid sequestants;  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 30 of 101  e. Ezetimibe (study -provided is allowed);  
f. Apheresis;  
g. Mipomersen or lomita pi[INVESTIGATOR_5328] (6 months prior to Visit S1);  
h. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (4 months prior to 
Visit S1, except PCSK9 small interfering RNA (siRNA), which are prohibited if used at any time in the past); 
i. Cholesteryl ester transfer protein (CETP) inhibitors (12 months prior to Visit S1);  
j. Red yeast rice extract -containing products ; 
k. Omega 3 fatty acids  and derivatives such as Lovaza
Â® and over-the-counter ( OTC ) fish 
oil;   
l. Systemic corticosteroids (within 5  weeks prio r to Visit T1; topi[INVESTIGATOR_298521]);  
m. The following therapi[INVESTIGATOR_298522] T2D:  rapid -acting and short- acting 
insulins including Lispro (HumaLogÂ®), Aspart (NovalogÂ®), Glulisine (AdipraÂ®), 
Novolin R/Novolin Regular, Humulin  R/Humulin Regular (except when used for 
basal delivery by [CONTACT_250877]); injectable GLP-1 agonists such as Exenatide (By[CONTACT_28557], By[CONTACT_28556]), liraglutide (Victoza
Â®), albiglutide (TanzeumÂ®) and dulaglutide 
(TrulicityÂ®); injectable synthetic forms of amylin such as Pramlintide (Symlin); and 
insulin glargine/lexisenatide (SoliquaÂ®) (within 3  months prior to Visit T1);  
18. The subject has planned initiation of or dosing changes in the following allowed drugs 
before or during the study: 
a. Oral diabetes medications  (within 3  months prior to Visit T 1);  
b. Intermediate -acting and long-acting insulin and insulin analogs when used for basal 
delivery of insulin including NPH, NovoLIN N, HumuLIN N, Glargine (Lantus), 
Determir (Levemir), NovoLIN 70/30, HumuLIN 70/30, NovoLog Mix 70/30 or HumuLOG Mix 70/30 (within 3 months prior to Visit T1),  
c. Rapid -acting and short-acting insulins only when used for basal infusion pump 
delivery (no bolus delivery allowed) including Lispro (HumaLog
Â®), Aspart 
(NovalogÂ®), Glulisine (AdipraÂ®), No volin R/Novolin Regular, Humulin R/Humulin 
Regular  (within 3  months prior to Visit T1),  
d. Obesity medication (within 3  months prior to Visit T1);  
e. Hormone replacement (within 5 weeks prior to Visit T1);  or 
f. Thyroid replacement (within 5 weeks prior to Visit T1);  
19. The subject has a medical or situational (ie, geographical) finding that, in the 
investigatorâ€™s opi[INVESTIGATOR_1649], may compromise the subjectâ€™s safety or ability to complete the 
study;  
20. The subject is an employee or contractor of the facility that is conducting the study or is a 
family member of the principal investigator, co -investigator, or any sponsor personnel. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364321] for a minimum of 10  hours prior to collection of all laboratory samples (water 
and concomitant medications, but not IMP are permitted).  
Beginning at screening, subjects  will be counseled to follow a healthy diet as per local or 
regional guidelines  and should be encouraged (as able) to participate in a stable, regular exercise 
program throughout the study.  
8.4. Investigator/Sponsor Suspension or Termination of Subject  
Enrollment  
If, in the opi[INVESTIGATOR_871], the clinical observations in the study suggest that it may be 
unwise to continue, the investigator may suspend or terminate the study after consultation with 
Esperion Therapeutics.  A written statement fully documenting the reasons for such a termination will be provided to Esperion Therapeutics (or designee) and to the institutional review board 
(IRB) . 
Esperion Therapeutics has the right to te rminate the study and remove all study materials from 
the investigational site.  A written statement will be provided to the investigator, the IRB, and 
regulatory authorities, if required.   
Possible reasons for termination of the study include, but are not limited to: 
â€¢ unsatisfactory enrollment with respect to quantity or quality , 
â€¢ inaccurate or incomplete data collection on a chronic basis ,  
â€¢ falsification of records , 
â€¢ failure to adhere to the protocol, and 
â€¢ lack of study oversight by [CONTACT_458] [INVESTIGATOR_1238]/or designee. 
In the event any serious or nonserious AEs occur, all documentation relating  to the event(s) must 
be obtained. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364322]  Dosage and Mode of 
Administration  
Subjects will receive one FDC -matched  PBO tablet and one EZE -matching PBO capsule once 
daily for 35  Â± 3 days during the run-in period prior to randomization. 
Subjects will be randomized to receive treatment with:  
â€¢ One (1) BA 180 mg + EZE 10 mg FDC tablet  and 1  EZE -matching PBO caps ule 
once daily for 84 Â± 3  days, or 
â€¢ One (1) EZE 10 mg overencapsulated tablet  and 1 FDC -matched PBO  tablet  once 
daily for 84 Â± 3  days; or 
â€¢ One (1) FDC -matched PBO  tablet and 1 EZE-matching PBO capsule once daily for 
84 Â± 3  days.  
All IMP will be taken orally,  at a similar time (approximate 24-hour intervals), in the morning 
with or without food.  
9.2. Description  of Investigational Medicinal Product  
9.2.1. Bempedoic Acid 180  mg + Ezetimibe 10 mg FDC Tablets , Ezetimibe 10 mg  
Overencapsulated Tablets,  and Matching Placebo 
Bempedoic acid 180 mg  + EZE 10 mg FDC tablets , EZE  10 mg  overencapsulated  tablets , FDC -
matched  PBO  tablets , and EZE -matching PBO capsule s will be provided by [CONTACT_298546].  A description of the tablets is provided in Table 1. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 33 of 101  Table 1: Description of Bempedoic Acid + Ezetimibe FDC Tablets, Ezetimibe Tablets  and Placebo  Tablets  
Parameter Bempe doic Acid + Ezetimibe 
FDC Tablet  Ezetimibe Overencapsulated 
Tablet  FDC- matched Placebo Tablet  Ezetimibe- matched Placebo 
Capsule  
Dosage form:  Film -coated tablet  Over -encapsulated tablets  Film -coated tablet  Capsules  
Unit dose:  180 mg bempedoic acid + 
10 mg ezetimibe 10 mg Not applicable  Not applicable  
Container:  Blister cards with child -resistant 
closures  Blister cards with child -resistant 
closures  Blister cards with child -resistant 
closures  Blister cards with child -resistant 
closures  
Route of admini stration:  Oral with water with or without 
food Oral with water with or without 
food Oral with water with or without 
food Oral with water with or without 
food 
Physical description: 
FDC = fixed -dose combination.  
 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 34 of 101  Please see Pharmacy Manual for detailed storage requirements and instructions and additional 
packaging and labeling information. 
9.3. Concomitant Medications  
Subjects will be instructed to report the use of any medication to the investigator and will be 
reminded about the importance of not taking any medications without consulting the 
investigator.  Subjects will be questioned about concomitant medication use at each study visit 
during the screening and treatment periods.  All prior medications, herbal remedies, dietary 
supplements, or vitamins that were taken within 3  months before screening (Visit S1) will be 
recorded.  Any concomitant medication that is taken from the time the first dose  of IMP is taken 
(Visit T1 ) throug h the EOS visit (Visit T3 ) or early termination from the study must be recorded, 
with indication, daily dose, and start and stop dates of administration. 
9.3.1. Prohibited Medications  
Use of any of the following drugs either in mono or combination therapy within 5  weeks prior to 
Visit T1 (unless otherwise stated) or a plan to use any of these drugs during the study is 
prohibited: 
Lipid -Modifying Therapi[INVESTIGATOR_014] (LMT) 
â€¢ Statins  including atorvastatin (Lipi[INVESTIGATOR_17133]Â®), fluvastatin (LescolÂ®), lovastatin (MevacorÂ®, 
Altoprevâ„¢), pravastatin (PravacholÂ®), rosuvastatin Calcium (CrestorÂ®), simvastatin 
(ZocorÂ®) and pi[INVESTIGATOR_2830] (LivaloÂ®); 
â€¢ Fibrates including gemfibrozil (LopidÂ®), fenofibrate (AntaraÂ®, LofibraÂ®, TricorÂ®, and 
Triglideâ„¢, LipantilÂ®, SupralipÂ®), clofibrate (Atromid -S), ciprofibrate (ModalimÂ®), 
bezafibrate (BezalipÂ®); 
â€¢ Niacin and derivatives including NiaspanÂ® Rx and OTC niacin (crystalline 
>500 mg/day or slow release or timed release at any dose);  
â€¢ Bile acid sequestants including Cholestyramine (QuestranÂ®, QuestranÂ® Light, 
PrevaliteÂ®, LocholestÂ®, LocholestÂ® Light); colestipol (ColestidÂ®); colesevelam HCl 
(WelCholÂ®, CholestagelÂ®); 
â€¢ Ezetimibe  (ZetiaÂ®, EzetrolÂ®) other than that which is study-supplied;  
â€¢ Lipid altering nutritional supplements including berberine, psyllium (MetamucilÂ®), 
green tea extract, si tostanol (found in oral nutritional supplements and some 
margarines, such as Benecol), beta-sitosterol (found in oral nutritional supplements 
and some margarines, such  as Promise Activ), pantothine and policosanol; 
â€¢ Apheresis;  
â€¢ Mipomersen  (KynamroÂ®) or lomitapi[INVESTIGATOR_5328] (JuxtapidÂ®) (within  6 months prior to 
Visit S1);  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 35 of 101  â€¢ PCSK9  inhibitors including evolocumab (RepathaÂ®) and alirocumab (PraluentÂ®) 
(within [ADDRESS_364323]); 
â€¢ CETP  inhibitors ( within 12 months prior to Visit S1); 
â€¢ Red yeast rice extract  (also known as monascus purpureus extract or Cholestin)-
containing products (within 5 weeks prior to Visit T1) ; 
â€¢ Omega 3 fatty acids and derivatives such as Lovaza and OTC fish oil; 
Other Prohibited Medications 
â€¢ Systemic corticosteroids (within 5  weeks prior to Visit T1); topi[INVESTIGATOR_298521];  
â€¢ The following therapi[INVESTIGATOR_298530] 1 or T2D:  rapid -acting and short -
acting insulins including Lispro (H umaLogÂ®), Aspart (NovalogÂ®), Glulisine 
(AdipraÂ®), Novolin R/Novolin Regular, Humulin R/Humulin Regular (except when 
used for basal delivery by [CONTACT_250877]); injectable GLP -1 agonists such as 
Exenatide (By[CONTACT_28557], By[CONTACT_28556]), liraglutide (VictozaÂ®), albiglutide (TanzeumÂ®) and 
dulaglutide (TrulicityÂ®); injectable synthetic forms of amylin such as Pramlintide 
(Symlin); and insulin glargine/lexisenatide (SoliquaÂ®) within  3 months prior to 
Visit T1; 
â€¢ Any experimental or investigational drugs within 30  days  before screening (Week -6, 
Visit S1).  Subject s who have enrolled in a study of an experimental siRNA inhibitor 
of PCSK9 are excluded.  
9.3.2. Allowed Medications  
Use of the following medications is allowed during the study:  
â€¢ oral diabetes medications if no changes in dose are made within 3 months before 
randomization (Visit T1/Day  1) or during the study; 
â€¢ Intermediate -acting and long-acting insulin and insulin analogs when used for basal 
delivery of insulin including NPH, NovoLIN N, HumuLIN N, Glargine (Lantus), 
Determir (Levemir), NovoLIN 70/30, HumuLIN 70/30, NovoLog Mix 70/30 or 
HumuLOG Mix 70/30 if no changes in dose are made within 3 months prior to 
Visit T1 ; 
â€¢ Rapid -acting and short-acting insulins only when used for basal infusion pump 
delivery  (no bolus deli very allowed)  including Lispro (HumaLogÂ®), Aspart 
(NovalogÂ®), Glulisine (AdipraÂ®), Novolin R/Novolin Regular, Humulin R/Humulin 
Regular if no changes in dose are made within 3 months prior to Visit T1 ; 
â€¢ obesity medications if no changes in dose have been made within 3 months before 
randomization (at Visit T1/ Day 1) or during the study;  
â€¢ hormone replacement therapy if no changes in dose are made within 5 weeks before randomization (at Visit T1/Day  1) or during the study; 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 36 of 101  â€¢ thyroid placement therapy if no changes in dose are made within 5 weeks before 
randomization (at Visit T1/Day  1) or during the study; and 
â€¢ topi[INVESTIGATOR_11930].  
Short- term use of a medication for a self -limiting indication (eg, acetaminophen for a headache) 
may be authorized by [CONTACT_093].  The maximum allowable dose of acetaminophen is 
2 g/day.  The investigator must make the decision to authorize use of such a medication only after consideration of the clinical situation, the potential for masking symptoms of a more 
significa nt underlying event, and whether use of the medication will compromise the outcome or 
validity of the study. 
9.3.3. Contraception  
Women of nonchildbearing potential are not required to use contraception.  Women of 
nonchildbearing potential are defined as those wh o are naturally postmenopausal (defined as 
â‰¥1 year w ithout menses and either a) â‰¥55 years old, or b) <55  years with an FSH level 
â‰¥40.0 IU/L) and those who are surgically sterile by [CONTACT_31658], bilateral oophorectomy, and/or tubal ligation.  
Women of childbearing potential must use [ADDRESS_364324] dose of IMP.  Acceptable 
methods of birth control include:  
a. placement of an IUD with or without hormones;  
b. established use of oral, implanted, topi[INVESTIGATOR_2855], or injectable, or hormonal method of 
contraception associated with inhibition of ovulation;  
c. barrier methods, including condom or occlusive cap with spermi cidal foam or 
spermicidal jelly;  
d. vasectomized male partn er who is the sole partner for the subject; and  
e. true abstinence when this is in line with the preferred and usual lifestyle of the subject.  Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.  
If a subject who is abstinent at the time the ICF is signed becomes sexually active, she must 
agree to use [ADDRESS_364325] dose on Day -1, the day prior to Visit T1.  During the Treatment P eriod, 
subjects  will receive double -blind IMP.  On  Day  1 (Visit T1), subj ects will be randomized to 
receive either FDC  or EZE or PBO , randomized 1:1:1.  Randomized assigned  blinded study drug 
will be dispensed to subjects according to the interactive web response system  (IWRS ).  During 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364326] research organization ( CRO ), and subject  
will all be unaware of subject â€™s treatment assignment.  
Blinding of treatment must be maintained for all subject s unless, in the opi[INVESTIGATOR_1070], the safety of the subject  may be at risk.  Only under the rarest of circumstances 
should the investigator consider breaking the blind and only when medical/supportive care 
cannot be provided without determining if the subject  is receiving active drug treatment.  In the 
event that the blind needs to be broken prior to completion of the study, the investigator should 
contact [CONTACT_282632].  If the blind must be broken prior to 
consultation with the Medical Monitor, contact [CONTACT_282633] [ADDRESS_364327] â€™s medical record the date, time, and reason for breaking the blind, and the names of 
personnel involved. 
Post-randomization values for individual laboratory measures for L DL-C, hs- CRP , non- HDL -C, 
TC, TG, and HDL -C that may inadvertently suggest treatment assignment will not be available 
to personnel from the clinical site, the subject , the Sponsor, or the CRO.  While knowledge of 
these values does not truly â€˜unblind,â€™ the c ollection of these lab assessments by [CONTACT_093], 
all collaborating physicians, or the subject s locally (outside the study visits) is strongly 
discouraged. Investigators should not perform testing of these analytes at the local lab during the 
conduct of the study. 
9.5. Investigational Medicinal Product  Adherence  
Subjects will be instructed to bring their IMP to each study visit beginning at Visit S3 and 
completing at Visit T3/EOS .  Compliance with dosing instructions will be assessed by [CONTACT_298547].  If the subject  has not taken 
multiple doses as instructed, the subject  will be queried for a reason, findings wil l be 
documented, and the subject will be counseled on the importance of carefully following all 
dosing instructions. Factors contributing to poor adherence will be determined and, if possible, 
remedied. Subjects demonstrating poor adherence during the Treatment Period will continue to 
be counseled on the importance of carefully following all dosing instructions, but will not be 
removed from the study. 
9.6. Overdose  
There is no specific antidote for an overdose of BA .  Management of an overdose should be 
focused on the treatment of symptoms.  These symptoms should be managed according to current standards of care with appropriate supportive measures.  Discontinuation of study drug 
should also be considered, as per medical judgement. 
Ezetimibe has been generally well tolerated in clinical trials in which healthy subjects (N  = 15) 
received 50  mg/day  of EZE for 14  days, subjects with primary hyperlipi[INVESTIGATOR_035] (N  = 18) received 
40 mg/day of EZE for up to 56 days, and subjects with homozygous sitosterolemia (N = 27) 
received 40  mg/day of EZE for up to [ADDRESS_364328] with homozygous 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 38 of 101  sitosterolemia took an accidental overdose of EZE 120 mg/day for 28  days with no reported 
clinical or laboratory AEs.  Symptomatic and supportive measures should be employed in the 
event of overdose. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364329] of the study.  Study medication will be stored under 
lock and key, with access limited to those authorized by [CONTACT_093], and will be managed according  to US Food and Drug Administration (FDA) regulations concerning the storage and 
administration of investigational drugs.  
Additional information regarding packaging, labeling, storage, and distribution is provided in the pharmacy manual . 
10.2. Administration of Investigational Medicinal Product  
The dose of IMP will be administered to the subjects at the study site at each of the study vi sits.  
The first dose of single -blind  PBO will be taken during Visit S2.  Subsequent doses will be self-
administered once daily by [CONTACT_298548] -1 (the day prior to Visit T1).  Double-blind IMP will be taken at 
Visit T1/Day  [ADDRESS_364330] dose of IMP will be taken on the morning of the day prior to Visit T3 /EOS ). 
Subjects will be instructed on the importance of maintaining 24-hour intervals between doses.  If 
the daily dose of IMP is not taken at the usual time due to unforeseen circumstances, the subject 
may t ake the dose as soon as possible after the target time but no later than noon.  If the daily 
dose is not taken by [CONTACT_18828], the subject will be instructed to skip the dose on that day and to 
resume dosing on schedule the next day. 
10.3. Investigation al Medicinal Product Accountability, Handling and 
Disposal  
The Principal I nvestigator must maintain accurate records of the receipt of all study medication 
shipped by [CONTACT_456]/sponsor representative and the disposition of that study medication. The 
Princi pal Investigator will ensure that all IMP is stored in a secured area, under recommended 
storage conditions  
 in accordance with applicabl e regu latory 
requirements for investigational drugs.  Access to IMP will be limited to those clinical site 
personnel authorized by [CONTACT_737].   
Upon comple
tion or termination of the study, all used and unused IMP ( FDC, EZE , and PBO ) 
will be returned  to the sponsor (or designee) for destruction or disposed of by [CONTACT_3452], per 

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364331] comply with applicable regulations, local 
law, and guidelines, and should include: 
â€¢ amount received/placed in storage area;  
â€¢ amount currently in storage area; 
â€¢ label identification or batch number; 
â€¢ dates and initials of person responsible for product inventory (including 
entry/movement/disposition); 
â€¢ date and amount dispensed to each subject, including unique subject identifier; 
â€¢ data returned by [CONTACT_1130], assessment of compliance, and relevant documentation of discrepancies ; 
â€¢ nonstudy disposition (eg, lost, broken, wasted); and  
â€¢ amount returned to sponsor/sponsor designee. 
The sponsor will provide forms to facilitate inventory control if the staff at the investigational 
site does not have an established quality system that meets the needs of this requirement. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364332] identification number (subject ID) will be assigned to identify each subject 
throughout the study and will be entered on all documentation.  If a subject is not eligible to receive treatment or discontinues from the study, that subjectâ€™s identification number cannot be 
assigned to another subject.  Subject identification numbers will be assigned sequentially. 
11.3. Rescreening  
Subject s who are screening failures due to stability requirements for a condition or concurrent 
medication or other reason may be considered for rescreening after consultation with the Sponsor (or designee).  If rescreened, these subjects  must also be re- consented  and screening procedures 
must be repeated.   If a subject  is a screen failure, or if a subject  discontinues from the study, their 
subject  ID number will not be assigned to another subject .  Rescreened subjects will be assigned 
a new subject ID number. 
11.4. Procedures and Schedule of Assessments 
The study is comprised of two distinct periods: the Screening and Run-in Period and the 
Treatment Period. The schedule of study events is provided in Appendix 1. However , a subject 
can be seen at any time for reasons of safety.  
All relevant data will be captured on electronic case report forms (eCRFs) according to the eCRF 
completion guidelines. 
11.5. General Visit Guid elines  
Subjects will arrive fasted and having not taken study medication prior to the visit. The following 
assessments will be conducted while fasted and prior to taking study medication (unless 
otherwise specified) : 
â€¢ Review of medical history, prior and concomitant medications ; 
â€¢ Assess AEs and SAEs; 
â€¢ PE; 
â€¢ Vital signs ; 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 42 of 101  â€¢ blood sampling for basic fasting lipid  assessments (LDL-C, non- HDL -C, TC, TG, 
HDL -C); 
â€¢ blood sampling for special lipi[INVESTIGATOR_298531] (apoB, hs- CRP , glucose, 
 HbA 1C); 
â€¢ blood sampling for clinical safety lab oratories . 
11.6. Screening Period  
11.6.1. Screening Period Visit  1 (Visit S1/Day -42 Â± 7) 
Subjects will be screened for study eligibility  at Visit S1  (Day -42 Â± 7) .  The following 
evaluations will be performed at this visit:  
â€¢ Written informed consent will be obtained before any study- related procedures are 
conducted. 
â€¢ Demographic data will be recorded.  
â€¢ Recent clinically relevant medical history will be recorded.  
â€¢ Prior, c oncomitant, and prohibited medications will be reviewed and recorded.  
â€¢ Weight (in kilograms) and height (in centimeters) will be measured, and BMI will be 
calculated.  
â€¢ PE 
â€¢ Vital signs (systolic blood pressure, diastolic blood pressure, and pulse rate) will be recorded.  
â€¢ Blood and urine specimens will be obtained for the following:  
âˆ’ serum pregnancy test (for surgically sterile women and women of childbearing potential) or FSH test (women  <55 years  old and â‰¥1 year without menses); 
âˆ’ basic fasting lipid panel; 
âˆ’ special lipi[INVESTIGATOR_298531] (HbA
1C only); 
âˆ’ coagulation panel; 
âˆ’ serum TSH ; 
âˆ’ clinical safety laboratories (hematology, clinical chemistry, and urinalysis ; 
âˆ’ urine drug screen . 
â€¢ eGFR will be calculated (by [CONTACT_12115]) using the MDRD formula.  
â€¢ Conduct diet and exercise counseling.  
â€¢ Contact [CONTACT_298549]. 

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364333] an HbA 1C between 7 %-10%,  an LDL- C level >70  mg/dL , and meet the 
other protocol inclusion/exclusion criteria based on initial screening will be contact[CONTACT_298550] (Visit S2) to occur approximately 7  days after Visit S1 . 
Subjects who fail to meet any entry criterion that can be assessed at Visit  S1 are considered to be 
screen failures and are not required to return for additional visits (although a subject  can be seen 
at any time for safety reasons).  
Under rare circumstances, subjects  who are considered to be screen failures due to not meeting 
stability requirements for a con dition or concurrent medication that is  considered to warrant 
rescreening after consultation with the Sponsor (or designee) may be rescreened.  These subjects 
must be re-consented, re-registered in the IWRS, and will have a new subject ID assigned.  
11.6.2. Screening Period Visit 2 (Visit S2/Day -35 Â± 3) 
Subjects  will undergo the following assessments and procedures at Visit S2 :  
â€¢ Review of all inclusion/exclusion criteria that can be assessed at this time ; 
â€¢ Concomitant and prohibited medication review (ongoing) ; 
â€¢ Adverse event s will be assessed (starting from signing of the informed consent); 
â€¢ Electrocardiogram (ECG) ; 
â€¢ Vital signs ; 
â€¢ Serology (including HBsAg, hepatitis  C antibody); 
â€¢ Conduct diet and exercise counseling; 
â€¢ Instruct subject to stop taking all LM T and other prohibited medications 
(Section  9.3.1); 
â€¢ Dispense s ingle -blind PBO  with instructions ; 
â€¢ Schedule next visit. 
11.6.3. Screening Period Visit 3 (Visit  S3/Day  -7 Â± 3 ) 
Subject s will undergo the following assessments and procedures at Visit S3: 
â€¢ Review of all inclusion/exclusion criteria ; 
â€¢ Concomitant and prohibited medication review (ongoing); 
â€¢ Adverse event s will be assessed ; 
â€¢ Weight (in kilograms);  
â€¢ Vital signs ; 
â€¢ Basic fasting lipi[INVESTIGATOR_805]; 
â€¢ Clinical safety laboratories ; 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 44 of 101  â€¢ Conduct diet and exercise counseling; 
â€¢ Assessment and recording of drug compliance with single -blind PBO ; 
â€¢ Schedule next visit. 
11.7. Treatment Period  
Enrollment criteria will be reviewed including sele ct laboratory values from Visit S3.  Subjects 
who have an LDL-C level between 100 to 220 mg/dL at Visit S3 and who meet all other 
inclusion/exclusion criteria will be scheduled for their first treatment visit (Visit T1/Day  1), and 
instruc ted to fast for a min imum of 10 hours (nothing but water) on the evening be fore reporting 
for Visit  T1/Day  1. 
11.7.1. Treatment Period Visit 1 (Visit T1/Day 1) 
Subjects will be scheduled for their first treatment visit approximately 7  days after completion of 
Visit S3/Day  -7.  Subjects will arrive at the study site after a minimum [ADDRESS_364334] dose of IMP at this visit. 
Procedures and  evaluations will be performed in the following order during this visit: 
â€¢ Enrollment criteria will be reviewed.  
â€¢ Concomitant and prohibited medications will be reviewed and recorded as needed.  
â€¢ Adverse event s will be assessed . 
â€¢ Weight (in kilograms) will be recorded . 
â€¢ Vital signs (systolic blood pressure, diastolic blood pressure, and pulse rate) will be 
recorded.  
â€¢ Blood and urine specimens will be obtained for the following: 
âˆ’ urine pregnancy test (for w omen of childbearing potential); 
âˆ’ basic fasting lipid panel; 
âˆ’ special lipi[INVESTIGATOR_298531]; 
âˆ’ clinical safety laboratories (hematology, clinical chemistry, and urinalysis ); 
âˆ’ reserve samp le for potent
ial exploratory biomarkers; and  
âˆ’ urine drug screen . 
â€¢ Subject will be given 1 serving of Ensure Original VanillaÂ® breakfast drink (Abbott 
Laboratories:  220 calories, 32 g of total carbohydrate)  at approximately 9:[ADDRESS_364335] the time of the meal. 
â€¢ Blood sample for PPG  (glucose only) will be collected 2 hours Â± [ADDRESS_364336] drink for the 2 -hour postprandial glucose 
assessment . 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 45 of 101  â€¢ Subjects will be randomized to a treatment ( once daily dosing of FDC, EZE, or PBO 
IMP). 
â€¢ Double-blind IMP will be dispensed and subject will be provided with dosing and 
storage instructions. 
â€¢ Subjects will take their first dose of IMP, with approximately 8  ounces of water, 
following collection of t he 2-hour PPG  blood glucose sample collection .   
â€¢ Conduct diet and exercise counseling. 
11.7.2. Treatment Period Visit 2 (Visit  T2/Day 28 Â± 3) 
Subjects will be scheduled for their second T reatment Period Visit approximately 27 days after 
completion of Visit T1 /Day  1.  Subjects will arrive at the study site after a minimum [ADDRESS_364337], having not yet taken the daily dose of IMP. 
Procedures and  evaluations will be performed in the following order during this visit: 
â€¢ Return of IMP; assessment and recording of IMP dosing adherence. 
â€¢ Concomitant and prohibited medications will be reviewed and recorded as needed.  
â€¢ Adverse event s will be assessed . 
â€¢ Vital signs (systolic blood pressure, diastolic blood pressure, and pulse rate) will be recorded.  
â€¢ Blood and urine specimens will be obtained for the following: 
âˆ’ basic fasting lipid panel; 
âˆ’ special lipi[INVESTIGATOR_298531]; 
âˆ’ clinical safety laboratories (hematology, clinical chemistry, and urinalysis ). 
â€¢ Subject will be given [ADDRESS_364338] drink (Abbott 
Laboratories:  220 calories, 32  g of total carbohydrate) at approximately 9:[ADDRESS_364339] the time of the meal. 
â€¢ Blood sample for PPG  (glucose only) will be collected 2 hours Â± [ADDRESS_364340] drink for the 2 -hour postprandial glucose 
assessment . 
â€¢ Double-blind IMP dispensed. 
â€¢ Subjects will take their daily  dose of IMP, with approximately 8 ounces of water, 
following collection of the 2-hour PPG  blood glucose sample collection .   
â€¢ Conduct diet and exercise counseling. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 46 of 101  11.7.3. Treatment Visit 3 (Visit  T3/EOS/Day 85 Â± 3) 
Subjects will be scheduled for their final T reatment Period Visit approximately 84 days after 
completion of Visit S1/Day  1.  Subjects will arrive at the study site after a minimum [ADDRESS_364341], having taken the fin al dose of IMP approximately 24-hours earlier on the previous day. 
Procedures and  evaluations will be performed in the following order during this visit: 
â€¢ Return of IMP; assessment and recording of IMP dosing adherence. 
â€¢ Concomitant and prohibit ed medications will be reviewed and recorded as needed.  
â€¢ Adverse events will  be assessed . 
â€¢ Weight (in kilograms) will be recorded . 
â€¢ PE. 
â€¢ Vital signs (systolic blood pressure, diastolic blood pressure, and pulse rate) will be 
recorded.  
â€¢ Blood and urine specimens will be obtained for the following: 
âˆ’ urine pregnancy test (for wo men of childbearing potential); 
âˆ’ basic fasting lipid panel; 
âˆ’ special lipi[INVESTIGATOR_298531]; 
âˆ’ clinical safety laboratories (hematology, clinical chemistry, and urinalysis )  
âˆ’ reserve sample for potential exploratory biomarkers. 
â€¢ Subject will be given [ADDRESS_364342] drink (Abbott 
Laboratories:  220 calories, 32  g of total carbohydrate) at approximately 9:[ADDRESS_364343] the time of the meal. 
â€¢ Sample fo r PPG blood glucose will be collected 2  hours Â± [ADDRESS_364344] drink for the 2- hour postprandial glucose assessment . 
â€¢ Subjects will be notified they may begin taking any LMT medications washed out 
during study participation at the conclusion of the visit. 
â€¢ Complete study status in IWRS (ie, early withdrawal or completed study).  
11.8. Subject Withdrawal Criteria 
11.8.1. Early Withdrawal f rom Study  
Subjects must re main in the study through Week  12 (Visit T3/Day  85 Â± 3) to be considered as 
having completed the study.  Subjects who prematurely withdraw from the study will be asked to 
continue to be followed for safety, as outlined in Appendix 1. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364345] whose health or 
well-being may be threatened by [CONTACT_298551].  Such subjects should be 
withdrawn from the study and should not be continued under a modified regimen. 
Subjects who are withdrawn from the study may not re-enter the study.  The reasons for study 
withdrawal may include:  
â€¢ Adverse event ; 
â€¢ Subject withdrawal of consent; 
â€¢ Failure to comply with the protocol; 
â€¢ Refusal to take IMP as indicated by [CONTACT_760]; 
â€¢ Illness, condition, or procedural complication that affects the subjectâ€™s ability to participate in the study or that requires prohibited medication ; 
â€¢ Sponsor or investigator terminates the study; 
â€¢ In the investigatorâ€™s judgment, it is in the subjectâ€™s best interest to discontinue participation in the study ; 
â€¢ Other (specify) . 
If a subject is lost to follow -up, study site personnel must make reasonable efforts to contact [CONTACT_298552]/w ithdrawal.  The measures that are taken to 
follow-up must be documented.   
11.8.2. Procedures for Early Withdrawal  
If a subject withdraws or is removed from the study for any reason, the subject should complete 
an End of Study visit.  Reason for withdrawal, date of the discontinuation, and date of the last 
dose of study drug should be recorded in the appropriate section of the eCRF.  Additionally, the discontinuation visit date must be registered in IWRS.  Study drug assigned to the withdrawn 
subject  may not be assigned to another subject. 
All effort should be made to have each subject complete all study visits on schedule according to 
the protocol.  Accommodations for early or late visits in special circumstances will be considered 
by [CONTACT_282640].  Written notice (regardless of cause) is to be 
provided within 48 hours of the withdrawal to the Sponsor personnel or the Medical Monitor.  At the time of discontinuation, every effort should be made to ensure all relevant procedures and 
evaluations scheduled for the final study visit are performed.  Except in the case of a medical 
emergency, the procedures and assessments detailed  in Appendix 1 for Visit T3/EOS will be 
performed upon the discontinuation of the study.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 48 of 101  12. ASSESSMENT OF PHARMACODYNAMICS   
12.1. Pharmacodynamic  Assessments  
12.1.1. Sample Collection, Storage, and Shippi[INVESTIGATOR_298532]  (LDL-C, non- HDL -C, TC, TG , and HDL- C), and Special 
lipi[INVESTIGATOR_156010] (apoB, hs-CRP, glucose, and HbA 1C) will 
be drawn with the subject in the seated position according the schedule of events described in 
Appendix 1.  All samples will be collected following a 10-hour fast with the exception of sample collected for the 2 -hour postprandial glucose assessment as described in Section  12.1.3.  
Laboratory samples will be collected by [CONTACT_298553] (provided by [CONTACT_2237]).  Reserve samples (serum and plasma) will be stored frozen for potential future measurement of 
additional BA  safety and efficacy biomarkers.  
12.1.2. Sample Collection, Storage, and Shippi[INVESTIGATOR_298532], and Special lipi[INVESTIGATOR_298533].  All samples will be collected following a [ADDRESS_364346] with the 
exception of sample collected for the 2 -hour postprandial glucose assessment as described in 
Section  12.1.2.  Laboratory samples will be collected by [CONTACT_298554] (provided by [CONTACT_11378]). 
12.1.3. Two -hour Postprandial Glucose  (PPG)  Assessment  
At Visits T1, T2 , and T3 following procedures described in Section  11.7; subjects will consume 
[ADDRESS_364347] drink (Abbott Laboratories:  220 calories, 32  g of 
total carbohydrate) at approximately 9:[ADDRESS_364348] the time of the start and 
completion of the meal.  The entire serving should be consumed within 5  minutes.   A PPG blood 
glucose sample will be collected 2  hours Â± [ADDRESS_364349] drink and processed for plasma per the laboratory manual.  The sample will be 
assessed by [CONTACT_2237] f or glucose.  
12.1.4. HOMA -IR and
HOMA- IR and  will be calculated from fasting glucose and insulin levels 
determined at Visit T1 (baseline), Visit T2 , and Visit T3/EOS using the following formulas 
described by [CONTACT_298555].
15  
HOMA-IR = fasting glucose x fasting insulin / 22.5 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 49 of 101  12.1.5. Exploratory Biomarker Measurement 
Additional exploratory safety, efficacy, or potential biomarkers may be assayed from serum and 
plasma  blood samples collected at Visits  T1 and T3 and stored frozen, reserved for potential 
future measurement of potential biomarkers.  
12.1.6. Clinical Laboratory Parameters (Basic Fasting Lipi[INVESTIGATOR_805], Special Lipi[INVESTIGATOR_298534] ) 
Blood specimens for basic fasting lipi[INVESTIGATOR_805], special lipi[INVESTIGATOR_805] , and other biomarker laboratory 
assessments will be collected as shown in  Table 2.  
Table 2: Clinical Laboratory Parameters (Basic Fasting Lipi[INVESTIGATOR_805], Special Lipi[INVESTIGATOR_298524])  
Clinical Laboratory Test  Clinical Laboratory Test 
Basic Fasting Lipid Parameters  Special Lipi[INVESTIGATOR_298535] 
â€¢ Calculated low -density lipoprotein cholesterol 
(LDL -C)  
â€¢ Non-high-density lipoprotein cholesterol (non -
HDL -C) 
â€¢ Total cholesterol (TC)  
â€¢ Triglycerides (TG)  
â€¢ High -density lipoprotein cholesterol (HDL- C) â€¢ High -sensitivity C -reactive protein (hs- CRP)  
â€¢ Apolipoprotein B (apoB) 
â€¢ Glucose 
â€¢ 
â€¢ 
â€¢ 
â€¢ Hemoglobin A 1C (HbA 1C) 
Additional Samples 
â€¢ Reserve blood samples for potential future 
measurement of biomarkers  
 

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364350]  at Visit S1 /Day  -42.  
Conditions that are relevant and/or clinically significant should be captured with at least a start 
date and an indication of whether the condition is ongoing or resolved.  All surgeries, regardless 
of date, should be reported. 
13.2. Vital Signs 
Systolic blood pressure, diastolic blood pressure, and pulse rate will be recorded according to the schedule of events ( Appendix 1).   Measurements should be taken after subject has been seated 
quietly for at least 5  minutes in a chair with the back supported, the feet flat on the ground, and 
the arms bared and supported at heart level. 
Blood pressure will be obtained using a calibrated, fully automated machine with a cuff that is 
appropriate to the size of the upper right arm.  If a fully automated machine is not available, 
blood pressure m ay be measured manually.  The same method (either automated or manual) and 
the same arm (right or left) must be used throughout the study. 
13.3. Weight, Height, and Body Mass Index  
Height  will be measured in centimeters (cm)  at Visit S1 only. Weight will be meas ured in 
kilograms (kg) on a calibrated scale in the morning while fasting, in street clothing, and after voiding at Visit S1, T1, and T3/EOS. 
Body mass index will be calculated as the weight in kilograms divided by [CONTACT_298556] (kg/m
2). 
13.4. Physical Examination  
A complete PE will be performed according to the schedule of events ( Appendix 1) or at early 
termination from the study.  A complet e PE includes an assessment of the following: 
â€¢ general appearance; 
â€¢ skin; 
â€¢ eyes, ears, nose, and throat (EENT); 
â€¢ head/neck ; 
â€¢ extremities ; 
â€¢ musculoskeletal examination ; 
â€¢ respi[INVESTIGATOR_76739] ; 
â€¢ cardiovascular assessment, including rhythm and presence of cardiac abnormalities ; 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 51 of 101  â€¢ abdominal examination ; 
â€¢ neurologic examination to record the presence of abnormalities in mental status, 
motor, and sensory function; and  
â€¢ any additional assessments necessary to establish baseline status or evaluate symptoms or adverse experi ences . 
Documentation of the PE will be included in the source documentation at the study site.  
Changes from baseline (Visit T1/Day  1) in PE findings that meet the definition of an AE will be 
recorded on the appropriate eCRF.  
13.5. 12-Lead Electrocardiograms 
A single 12-lead ECG will be obtained during screening at Visit S2 .  Additional 12- lead ECGs 
may be obtained at other times if clinically indicated.  The ECG should be obtained after the 
subject has rested quietly in the supi[INVESTIGATOR_21683] 10 minute s. 
13.6. Clinical Laboratory Tests  
13.6.1. Clinical Safety Laboratory Parameters 
Blood and urine specimens for safety laboratory assessments will be collected  as shown in 
Table 3. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 52 of 101  Table 3: Clinical Safety Laboratory Evaluations 
Clinical Laboratory Test Clinical Laboratory Test 
Hematology 
â€¢ Hematocrit (Hct)  
â€¢ Hemoglobin (Hgb) 
â€¢ Mean corpuscular hemoglobin (MCH) 
â€¢ Mean corpuscular hemoglobin concentration 
(MCHC)  
â€¢ Mean corpuscular volume (MCV)  
â€¢ Platelet count 
â€¢ Red blood (RBC) cell count 
â€¢ White blood (WBC) cell count with differential 
(absolute and %) Blood Chemistry (serum, fasting) 
â€¢ Albumin (Alb)  
â€¢ Alkaline phosphatase (ALK -P) 
â€¢ Alanine aminotransferase (ALT; serum glutamic pyruvic transaminase [SGPT])  
â€¢ Aspartate aminotransferase (AST; serum glutamic oxaloacetic transaminase [SGOT])  
â€¢ Blood urea nitrogen (BUN) 
â€¢ Calcium (Ca)  
â€¢ Carbon dioxide (CO2)  
â€¢ Chlo ride (Cl) 
â€¢ Creatinine  
â€¢ Creatine kinase (CK)  
â€¢ Glucose 
â€¢ Lactate dehydrogenase (LDH) 
â€¢ Phosphorus 
â€¢ Potassium (K) 
â€¢ Sodium (Na) 
â€¢ Total bilirubin (TB)
a 
â€¢ Total protein  
â€¢ Uric acid  Urinalysis (Dipstick)  
â€¢ Clarity  
â€¢ Bilirubin  
â€¢ Color 
â€¢ Glucose 
â€¢ Ketones 
â€¢ Leukocyte esterase  
â€¢ Nitrite  
â€¢ Occult blood 
â€¢ pH 
â€¢ Protein  
â€¢ Specific gravity  
â€¢ Urobilinogen 
Urinalysis (Microscopic) -only if urine dipstick 
abnormal 
â€¢ Bacteria  
â€¢ Casts  
â€¢ Crystals  
â€¢ Epi[INVESTIGATOR_1663]  
â€¢ RBC 
â€¢ WBC Coagulation (Visit S1 for all subjects, Visit T1 and 
3-7 days after Visit  T1 in subjects receiving 
anticoagulation therapy only) 
â€¢ Prothrombin time (PT) 
â€¢ International normalized ratio (INR) 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 53 of 101  Table 3: Clinical Safety Laboratory Evaluations 
Clinical Laboratory Test Clinical Laboratory Test 
Other Screening Labs Additional samples 
â€¢ Hepatitis B surface antigen (HBsAg) 
â€¢ Hepatitis C virus (HCV)b 
â€¢ Serum pregnancy test (only for females of 
childbearing potential)  
â€¢ Follicle -stimulating hormone (FSH; Females 
<55 years and â‰¥1 year without menses)  
â€¢ Urine pregnancy test prior to randomization (for female of child bearing potential) 
â€¢ Thyroid-stimulating hormone (TSH) â€¢ Hemoglobin A
1C (HbA 1C) 
a If TB â‰¥1.2  Ã— ULN, a  reflex indirect (unconjugated) bilirubin will be obtained.  
b If hepatitis  C antibody (HCV -AB) is positive, a reflex HCV RNA will be performed to rule out active disease.  
Subject s will be instructed to fast for a minimum of 10  hours before each blood draw; only water 
will be permitted during the fasting period.  If the subject  has not fasted for a minimum of 
[ADDRESS_364351]  in the seated position.  Laboratory samples will be 
collected by [CONTACT_298557] (provided by [CONTACT_2237]). 
13.6.3. General Monitoring and Management of Abnormal Clinical Laboratory Values 
The investigator will review the results of all laboratory tests as they become available and will sign and date the report to document their r eview.  The investigator will ascertain if any 
laboratory value is abnormal or represents a clinically significant change from baseline for the 
individual subject , with baseline defined as the last value or observation before the first dose of 
IMP.  The in vestigator may repeat the laboratory test or request additional tests to verify the 
results of the original laboratory test.  
If a laboratory value is determined to be an abnormal and clinically significant change from 
baseline for the subject , the investig ator will determine if it qualifies as an AE (as described 
below), and if yes, an appropriate eCRF will be completed.  All clinically significant laboratory 
abnormalities that occur  during the study that were not present at baseline should be followed 
and evaluated with additional tests , if necessary, until diagnosis of the underlying cause or 
resolution.  Specific monitoring and management guidelines for laboratories of special interest are outlined in the sections below. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 54 of 101  An abnormal laboratory value that is not already associated with an AE is to be recorded as an 
AE only if any one of the following criteria is met: 
â€¢ an action is taken with the  imp because of the abnormality;  
â€¢ intervention for management of the abnormality is required; or 
â€¢ the abnormality be deemed clinically  significant by [CONTACT_093]. 
[IP_ADDRESS]. Monitoring and Management of Elevated Liver Function Tests 
If a subject  has a new value >3  Ã— ULN for serum ALT and/or AST at any time after 
randomization, the subject  will undergo a repeat confirmatory liver function test (LFT) 
assessment as soon as is reasonably possible but preferably within 3 to 7 days after the laboratory 
result  is available.  
Repeat LFT assessment will include the following: (1)  measurement of serum ALT, AST, 
alkaline phosphatase, TB , direct bilirubin , and CK; prothrombin time (PT)/international 
normalized ratio (INR) ; eosinophil count; and antihepatitis A virus (total), HBsAg (confirmation 
of screening measurement), HCV (confirmation of screening measurement), and  
anticytomegalovirus/immunoglobulin M; (2) history of concomitant medication use; (3) history 
of exposure to environmental chemical agents, including ethanol; and (4) questioning for related 
symptoms.  Additionally, further testing, such as liver ultrasound or magnetic resonance imaging 
(MRI) scanning, may be warranted to rule out additional pathology depending on clinical presentation and should be discussed with the sponsor personnel or the authorized medical 
monitor. 
â€¢ If the repeat LFT assessment confirms that the value for serum ALT and/or AST is 
>3 Ã— ULN, consideration should be given to withdrawing the subject  and 
administering no further doses of IMP.  At the investigatorâ€™s discretion, IMP may be 
interrupted and the subject may be rechallenged with the IMP after values for the 
LFTs have returned to baseline levels.  
â€¢ If repeat LFT assessment confirms a value for serum ALT and/or AST >5 Ã— ULN, the 
subject  will be withdrawn from IMP treatment but will be asked to continue to be 
followed for safety (as outlined in the protocol- specified visit schedule in Appendix 1 
or more frequently as determined by [CONTACT_093] ). 
â€¢ If repeat LFT assessment confirms that the value for serum ALT and/or AST level is 
>3 Ã— ULN and the subject has any of the following findings, the subject  will be 
withdrawn from IMP treatment but will be asked  to continue to be followed for safety 
(as outlined in the protocol- specified visit schedule in Appendix 1 or more frequently 
as determined by [CONTACT_093] ): 
âˆ’ TB value >2  Ã— ULN ; 
Note: In th e case of subject s with Gilbertâ€™s disease, TB will be fractionated and 
the determination of 2 Ã— ULN will be based upon direct (conjugated) bilirubin. 
âˆ’ INR value >1.5  Ã— ULN (unless the subject  is on a stable dose of anticoagulation 
medication) ; 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 55 of 101  âˆ’ appearance or  worsening of right upper abdominal discomfort, anorexia, fatigue, 
nausea, vomiting, fever, rash, or eosinophilia. 
[IP_ADDRESS]. Monitoring and Management of Elevated Serum Creatinine Levels  
If a subject  experiences a decrease in eGFR to the level of 15 mL/min/1.[ADDRESS_364352]  will be withdrawn from IMP treatment but will be asked to 
continue to be followed for safety (as outlined in the protocol-specified visit schedule in  
Appendix 1). 
[IP_ADDRESS]. Monitoring and Management of Changes in Hemoglobin Levels 
If a subject  experiences a decrease of >2.0  g/dL (20  g/L) from baseline in Hgb at any time after 
randomization, the subject  will undergo a repeat confirmatory hematology testing as soon as is 
reasonably possible but preferably within [ADDRESS_364353] result becomes 
available.  
Repeat hematology assessment will include the following: (1)  measurement of Hgb, hematocrit 
(Hct) , mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration 
(MCHC), mean corpuscular volume (MCV), platelet count, reticulocyte count (percent and 
absolute), RBC count, and white blood cell (WBC) count with differential (absolute values only); (2) history of concomitant medication use; and (3) questioning for related symptoms.  
Additionally, further testing may be warranted to rule out additional pathology, depending on 
clinical presentation, and should be discussed with sponsor personnel or the authorized medical monitor.  
â€¢ If a repeat assessment confirms a decrease >2.0  g/dL (20  g/L) from baseline in Hgb 
concentration , the subject should be monitored carefully during the study and return 
at 2-week intervals after stu dy completion for additional Hgb measurement s until the 
Hgb concentration returns to baseline or reaches a stable level.  
â€¢ If a repeat assessment confirms a value <8  g/dL (80  g/L)  for Hgb, the subject  will b e 
withdrawn from IMP treatment.  The subject  will return at 1 -week  intervals after 
withdrawal of IMP treatment for additional Hgb  measurement s until Hgb 
concentration returns to baseline or reaches a satisfactory conclusion.  
â€¢ Subjects who are withdrawn from IMP treatment due to decreases in Hgb 
concentration will be asked  to continue to be followed for safety (as outlined in the 
protocol- specified visit schedule in Appendix 1). 
The investigator may choose to consult with a specialist at any time to further evaluate the cause 
of the alteration in  hemoglobin. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 56 of 101  [IP_ADDRESS]. Monitoring and Management of Elevated Creatine Kinase Levels  
If a subject  has a value >5 Ã— ULN  for serum CK at any time after randomization, the subject  will 
undergo a repeat confirmatory assessment as soon as is reasonably possible but preferably within 
3 to 7 days after the laboratory result is available .  This assessment will include questioning for 
related symptoms.  
â€¢ If the repeat CK assessment confirms an unexplained (ie, not associated with recent 
trauma or physically strenuous activity) CK abnormality (value >5 Ã— ULN ), the 
subject  should, if asymptomatic,  receive further assessment and investigation into the 
cause.  The presence of renal injury should be assessed , and serum CK levels should 
be measured approximately weekly or more frequently , if clinically indicated , until 
resolution.  If serum CK levels continue to rise, treatment with the IMP should be 
discontinued. 
â€¢ If symptomatic , the following steps should be completed: 
âˆ’ Hold dosing with the IMP; 
âˆ’ Clarify the nature, duration, and intensity of muscle symptoms; 
âˆ’ Review possible predisposing factors, such as unaccustomed exercise, heavy 
alcohol intake, viral illness (consider performing serology); 
âˆ’ Evaluate for additional diagnoses or other conditions, which can cause myopathy , 
including muscle tenderness (by [CONTACT_153056]), weakness, rash, measurement of serum 
creatinin e level , and dipstick urinalysis with microscopy , if indicated ; 
âˆ’ Obtain clinical chemistries to assess the possibility of lactic acidosis ; and  
âˆ’ Follow symptoms and serum CK levels until the abnormality has resolved. 
If, based on the above evaluation, an alternative explanation is suspected, consider 
resuming IMP once the serum CK level returns to baseline levels .  If no 
alternative explanation exists, c onsider withdrawing the subject from IMP 
treatment.  
â€¢ If the repeat assessment confirms an unexplained (ie, not associated with recent trauma or physically strenuous activity) CK abnormality (serum CK value 
>10 Ã— ULN ) even in the absence of symptoms, the subject  should be withdrawn from 
the study and given no further doses of IMP.  In all cases, signs/sym ptoms and 
laboratory evaluations, as outlined in the bulleted point above, should be evaluated. 
â€¢ If the subject  is withdrawn from IMP treatment, the subject  should be asked to 
continue to be followed for safety (as outlined in the protocol-specified visit schedule 
in Appendix 1).  
[IP_ADDRESS]. Monitoring and Management of Potential Hypoglycemia and Metabolic Acidosis 
Subject s will be e ducated on the signs and symptoms of hypoglycemia and will be instructed to 
report any signs and symptoms of hypoglycemia to the investigator. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364354] . 
13.7. Adverse and Serious Adverse Events  
13.7.1. Adverse Events  
[IP_ADDRESS]. Definition of Adverse Events  
An AE is any untoward medical occurrence in a clinical investigation subject  administered a 
pharmaceutical product, including control, and which does not necessarily have a causal relationship with treatment.  
An AE can be:  
â€¢ any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered r elated to the medicinal p roduct; 
â€¢ any new disease or exace rbation of an existing disease; 
â€¢ any deterioration in nonprotocol-required measurements of laboratory value or other 
clinical test (eg, ECG or x-ray) that results in symptoms, a change in treatment, or 
discontinuation from IMP; or 
â€¢ an adverse drug reaction (ADR; see Section  [IP_ADDRESS]). 
Treatment -emergent AEs are defined as AEs that begin or worsen after the first dose of IMP.  
[IP_ADDRESS]. Adverse Drug Reaction  
All noxious and unintended responses to a medicinal product related to any dose should be considered an ADR.  â€œResponsesâ€ to a medicinal product means that a causal relationship between a medicinal product and an AE is at least a reasonable possibility (ie,  the relationship 
cannot be ruled out). 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364355] information (eg, Investigator â€™s Brochure  for an 
unapproved investigational product or package insert/summary of product characteristics for an 
approved product). 
[IP_ADDRESS]. Reporting of Adverse Events  
All AEs that occur from the time the ICF is signed through [ADDRESS_364356] study visit should be reported to the sponsor per Section  [IP_ADDRESS].   
Subjects should be instructed to report any AE that they experience from the time the ICF is 
signed through [ADDRESS_364357] the ev ent on the appropriate eCRF.  
Wherever possible, a specific disease or syndrome rather than individual associated signs and symptoms should be identified by [CONTACT_256299].  However, if an observed or reported sign or symptom is not considered a component of a specific disease or 
syndrome by [CONTACT_093], it should be recorded as a separate AE on the eCRF.  Additionally, 
the condition that led to a medical or surgical procedure (eg, surgery, endoscopy, tooth extraction, transf usion) should be recorded as an AE, not the procedure.  
Any medical condition already present at screening or baseline should not be reported as an AE unless the medical condition or signs or symptoms present at baseline change in severity or seriousness a t any time during the study.  In this case, it should be reported as an AE. 
Clinically significant abnormal laboratory or other examination (eg, ECG) findings that are detected during the study or are present at baseline and significantly worsen during the study should be reported as AEs.  The investigator will exercise his or her medical and scientific 
judgment in deciding whether an abnormal laboratory finding or other abnormal assessment is 
clinically significant.  Significant abnormal laboratory values occurring during the clinical study will be followed until repeat tests return to normal, stabilize, or are no longer clinically 
significant.  Any abnormal test that is determined to be an error does not require reporting as an 
AE. 
Each AE is to be evaluat ed for duration, severity, seriousness, and causal relationship to the 
investigational drug.  For each AE, the following information will be recorded: 
â€¢ description of the event (eg, headache) ; 
â€¢ date of onset; 
â€¢ date of resolution (or that the event is continuing); 
â€¢ action taken because of the event ; 
â€¢ seriousness of the event; 
â€¢ severity of the event ; 
â€¢ outcome of the event; and  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 59 of 101  â€¢ investigatorâ€™s assessment of relationship to IMP. 
A cluster of signs and symptoms that results from a single cause should be reported as a si ngle 
AE (eg, fever, elevated WBC s, cough, abnormal chest x- ray, etc, can all be reported as 
â€œpneumoniaâ€). 
The investigator will carefully evaluate the comments of the subject  and the response to 
treatment in order that he/she may judge the true nature and severity of the AE.  The question of 
the relationship of AEs to IMP administration should be determined by [CONTACT_282645].  
Additional information will be collected regarding muscle -related AEs that may include, but may 
not necessarily be limited to, a muscle -related questionnaire, with questions regarding type of 
muscle -related symptoms, location of the muscle- related AE, and potential cause of the muscle-
related AE.  
[IP_ADDRESS]. Severity  
It is the investigatorâ€™s responsibility to assess the intensity (severity) of an AE.  The severity of 
the AE will be characterized as mild, moderate, or severe according to the following definitions: 
â€¢ Mild:  Events are usually transient and do not interfere with the subject â€™s daily 
activities . 
â€¢ Moderate:  Events introduce a low level of inconvenience or concern to the subject  
and may interfere with daily activities.  
â€¢ Severe:  Events interrupt the subject â€™s usual daily activity, are incapacitating with 
inability to do usual activities, or significantly affect clinical status and warrant intervention and/or close follow-up. 
Note :  A severe AE need not be serious and an SAE need not, by [CONTACT_108], be severe. 
[IP_ADDRESS]. Relationship  
It is the investigatorâ€™s responsibility to assess the relationship of the AE to both the IMP and EZE.  The degree of â€œrelatednessâ€ of the AE to the IMP and EZE should be described using the 
following scale:  
â€¢ Not Rela ted:  No temporal association and other etiologies are likely the cause. 
â€¢ Unlikely :  While cannot be definitively ruled as not related to IMP, a causal 
association is remote, and other etiologies are more likely to be the cause.  For 
reporting and summariza tion, events assessed as â€œUnlikelyâ€ to be related to IMP will 
be considered as â€œNot Relatedâ€ to IMP for regulatory reporting purposes.  
â€¢ Possible:  Temporal association, but other etiologies are likely the cause.  However, 
involvement of the IMP cannot be excluded. 
â€¢ Probable :  Temporal association, other etiologies are possible but unlikely.  The event 
may respond if the IMP is discontinued. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 60 of 101  â€¢ Definite :  Established temporal association with administration of the IMP with no 
other more probable cause.  Typi[INVESTIGATOR_897], the event should resolve when the IMP is 
discontinued and recur on re- challenge.  
[IP_ADDRESS]. Monitoring and Follow- up of Adverse Events  
Subject s having AEs will be monitored with relevant clinical assessments and laboratory tests, as 
determined by [CONTACT_093].  All follow -up results are to be reported to the sponsor personnel 
or the authorized medical monitor .  Any actions taken and follow up results must be recorded 
either on the appropriate page of the eCRF or in appropriate follow-up written correspondence, 
as well as in the subject â€™s source documentation.  Follow-up laboratory results should be filed 
with the subject â€™s source documentation. 
For all AEs that require the subject  to be discontinued from the study, relevant clinical 
assessments and laboratory tests must be repeated at appropriate intervals until final resolution, stabilization of the event(s), or until the subject  is lost to follow -up or dies. 
Subject s with AEs that are ongoing at study completion or study withdrawal must be followed 
until resolu tion or for [ADDRESS_364358].  
[IP_ADDRESS]. Treatment -Emergent Adverse Events  
Treatment -emergent AEs are defined as AEs that begin or worsen after the first dose of IMP. 
13.7.2. Serious Adverse Events  
[IP_ADDRESS]. Definition of Serious Adverse Event  
An SAE is defined as any AE occurring at any dose that results in any of the following outcomes:  
â€¢ results in death ; 
â€¢ is life threatening ; 
â€¢ requires inpatient hospi[INVESTIGATOR_1081]; 
â€¢ results in persistent or significant disability/incapacity, or substantial disruption of the 
ability to conduct normal life functions; 
â€¢ is a congenital anomaly/birth defect ; or 
â€¢ is an important medical event. 
Note : Hospi[INVESTIGATOR_31561] a formal inpatient admission.  This will not include 
admissions under â€œ23-hour Observational Status,â€ an emergency room visit without hospi[INVESTIGATOR_15517], or an urgent care visit and therefore such events will not be recorded as an SAE under 
this criterion, nor will hospi[INVESTIGATOR_298536].  However, unexpected complications and/or 
prolongation of hospi[INVESTIGATOR_282609].   Admission to the hospi[INVESTIGATOR_298537] 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 61 of 101  reasons (eg, no place to stay live too far away to come for hospi[INVESTIGATOR_6042]) will not be considered 
inpatient hospi[INVESTIGATOR_602].  
Important medical events that may not result in death, be life threatening , or require 
hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of suc h medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room, blood dyscrasias, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse. 
Any clinical endpoints th at meet SAE criteria will be also reported as SAEs.  
[IP_ADDRESS]. Definition of Adverse Events or Outcomes Not Qualifying as Serious Adverse 
Events  
The following are not considered SAEs and therefore do not need to be reported as such: 
â€¢ Preplanned or elective hospi[INVESTIGATOR_059] , including social and/or convenience situations 
(eg, due to inclement weather). 
â€¢ Overdose of either Esperion IMP or concomitant medication unless the event meets 
SAE criteria (eg, hospi[INVESTIGATOR_059]).  However, the event should still be captured as a 
nonserious AE on the appropriate eCRF page. 
[IP_ADDRESS]. Clinical Laboratory Assessments as Adverse Events and Serious Adverse Events  
It is the responsibility of the investigator to assess the clinical significance of all abnormal values as defined by [CONTACT_298558].  In some cases, significant changes in lab values within the normal range will require similar judgment.  Laboratory 
abnormalities should be reported as an AE if they meet any of the following criteria: 
â€¢ Intervention is re quired to treat the abnormality . 
â€¢ Modification of study treatment is required due to the abnormality. 
â€¢ Based on the investigatorâ€™s medical judgement . 
[IP_ADDRESS]. Reporting Serious Adverse Events  
All SAEs, regardless of relationship to IMP, occurring from the time of informed consent until 
[ADDRESS_364359] dose of IMP (for most subject s [ADDRESS_364360] wil l 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364361]  until the SAE has subsided or until the 
condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the subject dies.  
Within [ADDRESS_364362] update the SAE form and submit any supporting documentation (eg, subject  discharge summary or autopsy reports) to 
the safety designee.  
[IP_ADDRESS]. Reporting of Serious Adverse Events  to Regulatory Authorities 
The sponsor (and/or designee) is responsible for submitting expedited reports of suspected and unexpected serious adverse reactions (S[LOCATION_003]RS) to the appropriate regulatory authorities.  All investigators participating in ongoing clinical studies with the IMP will be notified by [CONTACT_103] (or designee) of S[LOCATION_003]Rs.  S[LOCATION_003]RS must be communicated as soon as possible to the appropriate IRB by [CONTACT_093], as applicable and/or reported in accordance with local laws and regulations.  Investigators should provide written documentation of IRB notification for each 
report to the sponsor. 
Serious AEs that are anticipated to occur in this subject  population will be collected and reported 
by [CONTACT_298559] S ection  [IP_ADDRESS] .  However, these events will not be 
submitted to the regulatory authorities as expedited reports unless they meet S[LOCATION_003]R criteria.  
The events that are considered exempt from expedited reporting include the following clinical 
endpoints: 
â€¢ cardiovascular death ; 
â€¢ nonfatal myocardial infarction ; 
â€¢ nonfatal stroke; 
â€¢ unstable angina requiring hospi[INVESTIGATOR_059]; 
â€¢ coronary revascularization ; 
â€¢ heart failure requiring hospi[INVESTIGATOR_059] ; and  
â€¢ noncoronary arterial revascularization . 
[IP_ADDRESS]. Reporting of Subject  Death  
The death of any subject  during the study or within the 30-day follow-up period after they have 
completed the study (regardless of the cause) must be reported as detailed above.  
[IP_ADDRESS]. Reports of Pregnancy  
Although not considered an SAE (unless the event occurs with a serious outcome), pregnancy information on female subjects will be collected by [CONTACT_298560].  If a female 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364363] pharmacovigilance including evaluation of AEs, PE 
findings, vital signs, and laboratory assessments.   
  

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 64 of 101  

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 65 of 101  

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 66 of 101  14. STATISTICS  
14.1. General Considerations  
The analyses described in this section will be performed as further outlined in the Statistical 
Analysis Plan, which will be finalized before the end of the study.  The analyses specified in the 
Statistical Analysis Plan will supersede those specified in the protocol in the event of any 
differences between the two documents.  A copy of the Statistical Analysis Plan will be included 
as an appendix in the clinical study report for this protocol. 
14.2. Determination of Sample Size  
The sample size of approximately 56 subjects per treatment arm (1:1:1) in this study (168 subjects total) is selected to provide adequate power for each of the co -primary endpoi nt as well 
as the co -primary endpoint family as a whole. 
14.3. Analysis Populations  
The following analysis populations will be defined: 
â€¢ The full analysis set (FAS) will be used for the pharmacodynamic analyses and will include all randomized subjects who receive at least [ADDRESS_364364] s in the FAS will be 
included in their randomized treatment group, regardless of the treatment they 
actually received . 
â€¢ Treatment Completer analysis set is a subset of full analysis set and will include 
subjects who complete 12- week treatment as indicated on the end of treatment CRF 
and have non- missing LDL -C value at Week 12 
â€¢ The safety population (SP) will include all subjects who receive at least 1  dose of 
IMP.  Subjects in the SP will be included in the treatment group that they actually 
received, regardless  of their randomized treatment.  
14.4. Disposition, Demographic, and Baseline Characteristics  
Disposition, including reason for withdrawal from the study, w ill be summarized by [CONTACT_6490].  Demographic and other baseline characteristics will be summarized by [CONTACT_298561] 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 67 of 101  using descriptive statistics (number, mean, median, standard deviation, minimum, and 
maximum) for continuous variables and counts an d percentages for categorical variables.  
14.5. Study Endpoints  
The primary objectives of this  study are demonstrated by 2 co-primary endpoints: 
â€¢ Percent change in LDL -C from baseline at Week  12 in FDC- treated arm compared to 
PBO -treated  arm;  
â€¢ Percent change in LDL -C from baseline at Week  [ADDRESS_364365] successfully demonstrate d its primary objective if  both co -
primary endpoints achieve statistical significance.  
Secondary Endpoints  
â€¢ Percent change from baseline at Week  12 in parameters below betwee n the FDC 
treated arm and EZE treated arm and PBO  treated arm:  
âˆ’ hs-CRP;  
âˆ’ Non-HDL -C; 
âˆ’ TC; 
âˆ’ apoB; 
âˆ’ TG; 
âˆ’ HDL -C; 
â€¢ Proportion of subject s attaining LDL -C <70 mg/dL at Week  12 in FDC- treated arm 
and EZE -treated  arm and  PBO -treated  arm;  
â€¢ Proportion of subject s achieving LDL-C reductions â‰¥ 50% from baseline at Week  12 
in FDC -treated arm and  EZE-treated arm and PBO -treated  arm.  
Safety Endpoints  
â€¢ Subject  incidence of TEAE;  
â€¢ Safety laboratory values, PE findings, and vital signs. 
Exploratory Assessments 
â€¢ Percent change from baseline at Wee
k 12 in parameters below between 
the FD
C-treated arm and EZE-treated arm and PBO -treated arm:  
âˆ’ HbA 1C; 
âˆ’ Plasma glucose (fasting and [ADDRESS_364366]-prandial); 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 68 of 101  âˆ’ HOMA-I
R index; 
 
14.6. Pharmacodynamic Analyses  
Descriptive statistics (number, mean, median, standard deviation, minimum, and maximum) will 
be used to summarize LDL-C, TC, HDL-C, non- HDL -C, TGs,  apoB, hs-CRP, glucose,  
 HbA 1C, HOMA- IR, , and 2- hour PPG levels at each 
assessment by [CONTACT_298562].  
The primary and secondary efficacy endpoint will be analyzed using analysis of covariance 
(ANCOVA), with treatment group  as a factor and baseline value as a covariate.   The ANCOVA 
will be performed using the FAS, with subject s included in their randomized treatment group 
regardless of the treatment they actually received. Subject s who  are missing their Week  [ADDRESS_364367] 
(LOCF).   The least squares mean (LSM) and standard error (SE) for percent change estimate will 
be provided for both treatment groups, along with the PBO -corrected LSM, its 95% confidence 
interval (CI) and associated p -value.  We will analyze observed data and LOCF data separately.  
The same analysis will be performed as sensitivity analysis on treatment completer set for 
primary and secondary efficacy endpoints. 
14.7. Exploratory Analyses  
For exploratory endpoints (change from baseline to Week 4 and Week  12 in HbA 1C, fasting 
glucose,  HOMA-IR index,  
and 2-hour PPG), the data will be analyzed in the similar fashion as for the primary endpoints.  For fasting plasma glucose, 
basel
ine is defined as the mean of the values 
from Week -1 (Visit S3) and predose Day  1/Week 0 (Visit T1); while baseline for HbA 1C, 2-hour 
PPG and  is the predose Day 1/Week  0 (Visit T1) value. 
14.8. Safety Analyses  
Treatment -emergent AEs  will be coded using MedDRA and will be categorized by [CONTACT_136492]. The subject incidence of all TEAE, S AEs, related AEs, AEs 
leading to withdrawal of study drug and/or study, fatal AEs, and AESI will be tabulated by [CONTACT_9313] (SOC) and preferred term in descending order of frequency and by [CONTACT_6490].  
Descriptive statistics (number, mean, median, standard deviation, minimum, and maximum) will 
be used to summarize actual values and change -from -baseline values for clinical laboratories an d 
vital signs at each postbaseline assessment by [CONTACT_9084].  All values will be evaluated for clinically notable results.  Data for additional safety parameters (eg, PE findings) will be listed by [CONTACT_1130].  
The AESI will be summarized as below . 

Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364368], and TB will be summarized.  All liver -associated laboratory abnormalities will be 
assessed for Hyâ€™s Law criteria (>3  Ã— ULN for either ALT or AST, wit h accompanying TB >2  Ã— 
ULN in the absence of other known causes) will also be applied to the data; any potential Hyâ€™s 
law cases will be listed separately.  
Musculoskeletal Safety  
AEs of muscle- related symptoms will be summarized by [CONTACT_1570].   In addi tion, the 
number and percent of subject s with abnormal CK values will be summarized.  
Hyperglycemia /Hypoglycemia/  
Cases of new onset or worsen events will be recorded as AEs and will be summarized using the appropriate SOC.  These events will be summarized by [CONTACT_282651]. 
Renal Safety  
Baseline eGFR and values of CK will be summarized by [CONTACT_1570] a nd by [CONTACT_298563].  Shift tables of eGFR category from bas eline over the study, will be provided by 
[CONTACT_1570].  
Neurocognitive Events  
Neurocognitive events will be identified and evaluated by [CONTACT_298564].  Summarization of neurocognitive events will occur using prespecifi ed 
MedDRA terms and will be performed by [CONTACT_1570]. 
Metabolic Acidosis  
Metabolic Acidosis events will be monitored by [CONTACT_298565].  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364369] ACCESS TO SOURCE DATA/DOCUMENTS  
15.1. Study Monitoring  
The sponsor (or its authorized repre sentative) has the obligation to follow this study closely to 
ensure that the study is conducted in accordance with the protocol, International Council for 
Harmonisation ( ICH) and Good Clinical Practice ( GCP ) guidelines, national regulatory 
requirements, and the current Declaration of Helsinki throughout its duration by [CONTACT_298566]â€™s facilities and other communications.  
These visits will be conducted to evaluate the progress of the study, to verify that the rights and well-being of the subjects are protected, and to verify that the reported clinical study data are 
accurate, complete, and verifiable from source documents.  This includes review of ICFs, results 
of tests performed as a requirement for participation in this study , and any other medical records 
(eg, laboratory reports, clinic notes, investigational medicinal product dispensing log, pharmacy 
records, subject sign-in sheets, subject-completed questionnaires, telephone logs) that are 
required to confirm information contained on the eCRFs. 
The monitoring strategy for the study foresees a risk-based monitoring approach, in line with the 
relevant FDA recommendations, and will be described in detail by [CONTACT_1758]- specific risk -based -
monitoring plan. 
A monitoring visit should include a review of the essential clinical study documents (regulatory 
documents, eCRFs, medical records and source documents, drug disposition records, ICFs, etc), 
as well as discussion on the conduct of the study with the investigator and staff.  These 
documents should be redacted by [CONTACT_298567]. 
The monitor should conduct these visits as frequently as appropriate for the clinical study.  The 
investigator and staff should be available during these visits for discussion of the conduct of the 
study, as well as to facilitate the review of the clinical study records and resolve/document any discrepancies found during the visit.  
All monitoring activities will be reported and archived.  In addition, monitoring visits will be 
documented at the clinical site by [CONTACT_76775] -specific monitoring log. 
15.2. Audits and Inspections  
Representatives of the sponsor or its authorized clinical quality assurance group may visit a clinical site at any time during the study to cond uct an audit of the study in compliance with 
regulatory guidelines and company policy.  These audits will require access to all study records, including source documents, for inspection and comparison with the eCRFs.  Subject privacy must be respected.  Th e investigator and clinical site personnel are responsible for being present 
and available for consultation during routinely scheduled site audit visits conducted by [CONTACT_298568].  
The clinical study may also be inspected by  [CONTACT_298569], as well as the applicable regulations and guidelines.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 71 of 101  16. QUALITY CONTROL AND QUALITY ASSURANCE  
To ensure compliance with GCP and all applicable regulatory requirements, the 
sponsor/designee may conduct a quality assurance audit (see also Section  15.1).  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364370]/Independent Ethics Committee Approval  
Before initiation of the study, the investigator must obtain approval or favorable opi[INVESTIGATOR_180140], ICF, and any material related to subject recruitment from an IRB.  The IRB 
must comply with the provisions specified in 21 Code of Federal Regulations (CFR) Part  56, 
ICH and GCP guidelines, and applicable pertinent state and federal requirements . 
Institutional review boards must be constituted according to the applicable laws.  It is the 
responsibility of each investigational site to submit the protocol, Investigatorâ€™s Brochure, subject 
ICF for the study, subject recruitment materials (if applicable), and o ther documentation as 
required to its IRB for review and approval.  A copy of the written approval must be provided to 
the sponsor. 
The documentation should clearly mention the approval/favorable opi[INVESTIGATOR_29925], the 
subject ICF, and subject recrui tment materials (if applicable), including respective version dates.  
The written approval and a list of the voting members, their titles or occupations, and their institutional affiliations must be obtained from the IRB and provided to the sponsor before the release of clinical study supplies to the investigational site and commencement of the study.  If 
any member of the IRB has direct participation in this trial, written notification regarding his or 
her abstinence from voting must also be obtained. 
Clinical sites  must adhere to al l requirements stipulated by [CONTACT_298570].  This includes 
notification to the IRB of protocol amendments, updates to the subject ICF, recruitment materials 
intended for viewing by [CONTACT_1766], aggregate safety reports required by [CONTACT_282657], serious and unexpected AEs, reports and updates regarding the ongoing review of the 
study at intervals specified by [CONTACT_35974], and submission of final study reports and 
summaries to the IRB.  
It is the respons ibility of the clinical site to submit information to the appropriate IRB for annual 
review and annual re-approval. 
The investigator must promptly inform the IRB of all SAEs or other safety information reported 
from the subject or sponsor. 
17.2. Ethical Conduct of the Study  
The investigator agrees, when signing the protocol, to conduct the study in accordance with 
ethical principles (21  CFR Parts  11, 50, 54, 56, 312, 314, and 320) that have their origin in the 
current revision of the Declaration of Helsinki and t hat are consistent with GCPs, applicable 
regulatory requirements, and policies and procedures as outlined by [CONTACT_76778].  
The investigator agrees to allow monitoring and auditing of all essential clinical study document s 
by [CONTACT_298571].  Monitoring and auditing visits by [CONTACT_298572].  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364371] sign the â€œInvestigator 
Signatureâ€ page ( Appendix 3) and return it and a copy of a current curriculum vitae to the 
sponsor.  For this study and all studies conducted under an investigational new drug application 
(IND), the investigator must sign and return a completed Form FDA 1572 â€œStatement of 
Investigatorâ€ to the sponsor (or designee). 
17.3. Written Informed Cons ent 
The investigator will ensure that the subject is given full and adequate oral and written 
information about the nature, purpose, and possible risks and benefits of the study.  Subjects must a lso clearly understand that they are free to discontinue from the study at any time.  The 
subject should be given the opportunity to ask questions and allowed time to consider the information provided. 
The subjectâ€™s signed and dated informed consent must be obtained before conducting any study 
procedures on the sponsor- approved ICF.  
The investigator must maintain the original, signed ICF.  A copy of the signed ICF must be given 
to the subject in accordance with the IRB reporting guidelines. 
17.4. Subject Confidentiali ty 
The names and identities of all research subjects will be kept in strict confidence and will not appear on eCRFs or other records that are provided to or retained by [CONTACT_456] (or authorized representative).  If a subjectâ€™s name [CONTACT_21016] o n any document, it must be redacted and replaced 
with the subject identifier before a copy of the document is supplied to the sponsor (or authorized representative).  The ICF must include appropriate statements explaining that subject data will be confidential and the actions that will be taken to ensure subject confidentiality.  
Any other confidentiality requirements specified by [CONTACT_779], IRB, or local regulations will be adhered to and detailed appropriately in the ICF. 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364372] KEEPI[INVESTIGATOR_1645]  
18.1. Inspection of Records  
Applicable regulations require the sponsor (or authorized representative) to inspect all 
documents and records to be maintained by [CONTACT_093], including but not limited to, medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) for the subjects in this study.  These regulations also allow the 
sponsor records to be inspected by [CONTACT_76782].  The investigator will permit study -related monitoring, audits, IRB review, and regulatory inspections 
by [CONTACT_298573]/documents.  Direct access includes permission to 
examine, analyze, verify, and reproduce any records and reports that are important to the evaluation of a clinical study.  
18.2. Retention of Records 
In compliance with the ICH/GCP guidelines, the investigator/institution agrees to retain and 
maintain all study records that support the data collected from each subject , as well as all study 
documents, as specified in ICH/GCP, Section [ADDRESS_364373] be contact[CONTACT_180219].  Under no circumstances shall the 
investigator relocate or dispose of any study documents before having obtained written approval 
from the sponsor. 
Essential records (including eCRFs, source documents, study drug disposition records, signed 
subject  ICFs, AE reports, and other regulatory documents), as required by [CONTACT_108127], must be maintained for [ADDRESS_364374]. 
It is the responsibility of the sponsor to inform the investigator/Institution as to when these 
documents no longer need to be retained. 
18.3. Electronic Case Report Forms and Study Records  
Access to eCRFs will be provided to the clinical site.  As part of the responsibil ities assumed by 
[CONTACT_6231], the investigator agrees to maintain adequate case histories for the 
subjects treated as part of the research under this protocol.  The investigator agrees to maintain 
accurate source documentation and eCRFs as part of the case histories.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 75 of 101  Study records are comprised of source documents, eCRFs, and all other administrative 
documents ( eg, IRB correspondence, clinical trial materials and supplies shipment manifests, 
monitoring logs, correspondence).  A study- specifi c binder will be provided with instructions for 
the maintenance of study records.  
Source documentation is defined as any hand written or computer-generated document that 
contains medical information or test results that have been collected for or is in support of the protocol specifications (eg, laboratory reports, clinic notes, drug disbursement log, pharmacy 
records, subject sign in sheets, subject-completed questionnaires, telephone logs, x- rays, ECGs ).  
All draft, preliminary and pre/final iterations of  a final report are also co nsidered to be source 
documents (eg, faxed laboratory reports and hard copy laboratory reports, faxed initial results, and hard copy, final report).   
The investigator agrees to allow direct access to all essential clinical study  documents for 
purposes of monitoring and/or auditing by [CONTACT_298574]. 
Data reflecting the subjectâ€™s participation with the IMP under investigation are to be reported  to 
the sponsor.  The data is to be recorded on the eCRFs and/or other media provided or approved 
by [CONTACT_456].  
A completed eCRF must be submitted for each subject who receives IMP, regardless of duration.  
All supportive documentation submitted with the eCRF, such as laboratory or hospi[INVESTIGATOR_1097], should be clearly identified with the study and subject number.  Any personal information, 
including subject name, should be removed or rendered illegible to preserve individual confidentiality.  The eCRF should not be used as a source document unless otherwise specified 
by [CONTACT_456].  
Neither the sponsor nor a service provider contracted to analyze data and complete the study 
report is permitted to interpret a blank answer; therefore, all fields should be c ompleted.  All 
requested information must be entered on the eCRFs.  If an item is not available or is not 
applicable, this fact should be indicated as (N/A) not available or (N/D) not done; do not leave a space blank.  
Each set of completed eCRFs must be si gned and dated by [CONTACT_298575].  The completed database is to be returned to Esperion Therapeutics as soon as practical after completion by [CONTACT_76787].  
It is essential that all dates appearing on the sponsorâ€™s subject data collection forms for 
laboratory tests, cultures, etc, be the dates on which the specimens were obtained or the procedures performed.  The eCRFs will be signed or countersigned by [CONTACT_298576].  All data collection forms should be 
completed within  a timely manner, according to the eCRF completion guidelines, following the 
evaluation . 
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364375] agree to the responsibilities and obligations listed below, as specified by 
[CONTACT_76789]/GCP guidelines: 
â€¢ Agree to conduct the study in accordance with the relevant current protocol; 
â€¢ Agree to personally conduct or supervise the described investigation(s); 
â€¢ Agree to inform any subjects, or persons used as controls, that the investigational 
medicinal products are being used for investigational purposes and ensure that the 
requirements relating to obtaining informed consent and IRB review and approval are 
met; 
â€¢ Agree to report adverse experiences that occur during the investigation ; 
â€¢ Read and understand the information in the Investigatorâ€™s Brochure, including the potential risks and side effects of the investigational medicinal product; 
â€¢ Ensure that all associates, colleagues, and employees assisting in the conduct of the study are informed about their obligations in meeting the above commitments; 
â€¢ Maintain adequate and accurate records and make those r ecords available for 
inspection; 
â€¢ Ensure that an appropriate IRB will be responsible for the initial and continuing review and approval of the clinical investigation; 
â€¢ Agree to promptly report to the IRB all changes in the research activity and all 
unanticipated problems involving risks to subjects or others; 
â€¢ Agree not to make changes in the research without IRB approval, except where 
necessary to eliminate apparent hazards to subjects ; 
â€¢ Comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements. 
Refer also to:  
âˆ’ FDA Regulations Related to GCP and Clinical Trials: http://www.fda.gov/oc/gcp/regulations.html 
âˆ’ Guidance and Information Sheets on GCP in FDA- Regulated Clinical Trials: 
http://www.fda.gov/oc/gcp/guidance.html 
âˆ’ Guidance for IRBs and Clinical Investigators: http://www.fda.gov/oc/ohrt/irbs/default.htm 
âˆ’ Guidance for Industry â€“ E Good Clinical Practice: Consolidated Guidance: http://www.fda.gov/cder/guidance/959fnl.pdf 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 77 of 101  19.2. Study Administrative Structure  
Medi cal and Safety Monitoring: 
 
Cell phone:
Email:
Central Laboratory: Details are provided in the laboratory manual 
Bioanalytical Laboratory: 
IMP
 Supply Chain  Details are provided in the pharmacy manual 
eCRF and Database: Details are provided in the CRF Completion Guidelines 
19.3. Amendments  
Changes to the research covered by [CONTACT_282667].  All amendments to the protocol must be initiated by [CONTACT_298577].  Protocol amendments must not be implemented without prior IRB.  
Documentation of amendment approval by [CONTACT_298578].  When the change(s) involve only logistic or administrative aspects of the study, the IRB only needs to be notified.  
In situations in which a departure from the protocol is unavoidable, the investigator will contact 
[CONTACT_7195].  Except in emergency situations, this contact [CONTACT_41042].  In all cases, contact [CONTACT_298579].  The data recorded on the eCRF and source documents will reflect any departure from the protocol and the source documents will describe the departure and the circumsta nces requiring it.  
19.4. Financial Disclosure  
Prior to the start of the study, investigators will release sufficient and accurate financial 
information that permits the sponsor to demonstrate that an investigator and all study relevant 
assigned personnel have no personal or professional financial incentive regarding the future 
approval or disapproval of the study drug such that his or her research might be biased by [CONTACT_76790].  

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 78 of 101  20. PUBLICATION AND DISCLOSURE POLICY  
It is understood by [CONTACT_298580]â€™s staff and associates as may be necessary to conduct 
this clinical study.  
All information derived from this clinical study will be used by [CONTACT_456] (or designee) and, 
therefore, may be disclosed by [CONTACT_456] (or designee), as required, to other clinical 
investigators, to the FDA, to other government agencies, or in connecti on with intellectual 
property filings or publications.  To allow for the use of the information derived from this 
clinical study, it is understood by [CONTACT_298581] a from this clinical study.  The investigator agrees 
to maintain this information in confidence, to use the information only to conduct the study, and 
to use the information for no other purpose without the sponsorâ€™s prior written consent (or as 
otherwise may be permitted pursuant to a written agreement with the sponsor or its designee).  
The results of the study will be reported in a clinical study report prepared by [CONTACT_456] (or 
designee), which will contain eCRF data from all clinical sites that conduc ted the study. 
The sponsor shall have the right to publish data from the study without approval from the investigator.  Manuscript(s) and abstract(s) may only be prepared through cooperation between the sponsor (or designee) and the study investigator(s).  If an investigator wishes to publish 
information from the study, a copy of the manuscript must be provided to the sponsor for review 
in accordance with the provisions of such investigatorâ€™s written agreement with the sponsor (or designee) before submission for publication or presentation.  If requested by [CONTACT_170196], the investigator will withhold such publication in accordance with the provisions of such 
agreement.  
Bempedoic Acid 180 mg + Ezetimibe  [ADDRESS_364376] OF REFERENCES 
1. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. 
Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction 
from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A- I 
and B, and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) 
Study. Circulation. 2001;104:1108-13. 
2. World Health Organization (WHO) Fact Sheet No 317 Updated May  2017. 
3. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 
2014: epi[INVESTIGATOR_282615]. Eur Heart J. 2014; 35:2950-9. 
4. Mozffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al, for the writing group Members. Heart Disease and Stroke Statistics â€”2015 Update. A Report 
from the American Heart Association. Circ. 2015;131:e29-322. 
5. Stone NJ, Robinson J, Lic htenstein AH, Bairey Merc CN, Blum CB, Eckel RH, et al. 
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American 
Heart Association Task For ce on Practice Guidelines. Circulation. 2014 
Jun 24;129([ADDRESS_364377] 2):S1 -45. doi: 10.1161/01.cir.[PHONE_5875].[ZIP_CODE].7a 
6. Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascula r events. New Engl 
J Med. 2008:358;12:1240-9. 
7. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Cholesterol Treatment Trialistsâ€™ (CTT) Collaboration. Efficacy and safety of more intensive lowering 
of LDL cholesterol: a meta -analysis of data from 170 000 participants in 26 randomised 
trials. Lancet. 2010;376:1670-81. 
8. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction: A meta-regression analysis. J Am Coll Cardiol. 2005 Nov 15;46(10):1855-62. Epub [ADDRESS_364378] 24. 
9. Stamler J, Wentworth D, Neaton J. Is relationship between serum cholesterol and risk for premature death from coronary heart disease continuous and graded? JAMA. Nov 28 1986;256(20):2823-8. 
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapyâ€“Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with 
statins after acute coronary syndromes . New Engl J Med. 2004;350:1495-504. 
11. Jacobson TA for the NLA Task Force on Statin Safety - 2014 update. J Clin Lipi[INVESTIGATOR_37487]. 
2014;8:S1-4. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 80 of 101  12. Cannon CP, Blazing MA, Guiglian RP, McCagg A, White JA, Theroux P, et al, for the 
IMPROVE -IT Investigators. Ezetimibe added to statin therapy after acute coronary. N 
Engl J Med. 2015;372(25):2387-97. 
13. Investigatorâ€™s Brochure, Bempedoic Acid (ETC -1002), v12.0, Release Date 07  December  
2017. 
14. Ezetimibe  Tablets  [internet, cited [ADDRESS_364379]  2017]. Available from: 
https://www.sasrxmedical.com/documents/pdf/PI_Par_Ezetimibe_12-2016.pdf. 
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: 
Homeostasis model assessment: insulin resistance and beta -cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia 1985(28):412-419. 
16. Thompson PD, Clarkson P, Karas RH. Statin- associated myopathy. JAMA. 
2003:289:1681-90. 
17. Food and Drug Administration (2012). FDA announces safety changes in labeling for 
some cholesterol -lowering drugs [Press release]. Available from 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm  
18. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipi[INVESTIGATOR_37487]. 2001(12):105-12. 
19. Dietschy JM, Turley SD. Cholesterol metabolism in the central nervous s ystem during 
early development and in the mature animal. J Lipid Res. 2004(45):1375-97. 
20. Goedeke L, Fernandez -Hernando C. microRNAs: A connection between cholesterol 
metabolism and neurodegeneration. Neurobiol Dis. 2014(72):48-53. 
 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 81 of 101  22. APPENDICES  
Appendix 1  Schedule of Assessments   
Appendix 2  Sponsor Signature   
[CONTACT_76798] 3  Investigator Signature   
[CONTACT_76798] 4  Summary of Changes Amendment 1  
 
 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058 Amendment 1, 14 March 2018 
 
 
Confidential Page 82 of 101  APPENDIX 1. SCHEDULE OF ASSESSMENTS  
 Study Period:  Screening and Run- in Treatment  
 Study Visit:  S1 S2 S3 T1 T2 T3/EOSa 
 Study Week:  -6 -5 -1 1 4 12 
Procedure Study Day:  -42 Â± 7 -35 Â± 3  -7 Â± 3  1 28 Â± 3  85 Â± 3  
Informed consent  X      
Inclusion/Exclusion criteriab X X X X   
Demographics  X      
Medical history  X      
Prior and/or Concomitant medications  X X X X X X 
Adverse event recording   X X X X X 
Physical examination  X     X 
Weight /BMI c X  X X  X 
Height  X      
12-Lead ECGd  X     
Vital signse X X X X X X 
Serum pregnancy test/ FSHf X      
Urine pregnancy testh    X  X 
Basic fasting lipid panelg X  X X X X 
Special lipi[INVESTIGATOR_298538] X   X X X 
Coagulation paneli X      
TSH  X      
Serologyj  X     
Clinical safety laboratoriesk X  X X X X 
Urine drug screen X   X   
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058 Amendment 1, 14 March 2018 
 
 
Confidential Page 83 of 101   Study Period:  Screening and Run- in Treatment  
 Study Visit:  S1 S2 S3 T1 T2 T3/EOSa 
 Study Week:  -6 -5 -1 1 4 12 
Procedure Study Day:  -42 Â± 7 -35 Â± 3  -7 Â± 3  1 28 Â± 3  85 Â± [ADDRESS_364380] drinkm    X X X 
PPG glucose samplen    X X X 
Diet and exercise counseling  X X X X X  
Dispense single -blind IMP   X     
Return single -blind IMP and assess dosing 
adherence    X X   
Dispense double -blind IMP     X X  
Return double -blind IMP and assess 
dosing adherence      X X 
ApoB  = apoprotein  B; BMI = body mass index; ECG = electrocardiogram; eGFR  = estimated glomerular filtration rate; EOS = end of study; FSH = follicle -
stimulating hormone; HbA1c  = hemoglobin A1c; HbsAg  = hepatitis  B surface antigen; HCV -AB = hepatitis C virus antibody; HDL -C = high-density 
lipoprotein cholesterol; hs -CRP  = high-sensitivity C -reactive protein; IMP  = investigational medicinal product; LDL -C = low-density lipoprotein cholesterol; 
TC = total cholesterol; TG  = triglycerides; TSH  = thyroid -stimulating hormone.  
a All procedures will be completed at EOS or at time of early termination from the study . The last dose of IMP will be taken on the morning of Day  84 or the day 
prior to Visit T3/EOS.  Visit T3/Day  [ADDRESS_364381] a fasting calculated LDL -C level between 100 and 220  mg/dL after 5-week washout of all LDL -C-lowering drugs and nutritional 
supplements.  If TG level is >400  mg/dL, a repeat  assessment may be obtained; the repeat assessment will be used to determine study eligibility and screening 
will be extended by [ADDRESS_364382] 5 minutes in a chair with 
the back supported, the feet flat on the ground, and the arms bared and supported at heart level.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058 Amendment 1, 14 March 2018 
 
 
Confidential Page 84 of 101  f Pregnancy tests will be obtained for women of childbearing potential and for surgically sterile women; FSH level will be obtained for women  <55 years  old and 
â‰¥1 year without menses . 
g Basic  fasting lipid panel includes calculated TC, calculated LDL -C, HDL -C, calculated non -HDL -C, and TG s. 
h Special lipi[INVESTIGATOR_298539], hs -CRP, glucose, and HbA 1C.   
i Coagulation panel (see  Table  3) will be performed only at Visit S1/Day  -[ADDRESS_364383] is receiving an anticoagulant agent in which case the coagulation 
panel will be repeated at Visit T1/Day  1 and 3 to 7 days after  starting the IMP.  
j The serology assessment includes HbsAg and HCV -AB. 
k Clinical safety laboratories include hematology, clinical chemistry, and urinalysis; the required assays are listed in  Table  3.  
l Reserve blood sample for potential future exploratory biomarkers wil l be collected at Visits  T1 and  T3; separated into K2 -edta plasma and serum separator 
tubes; and processed plasma and serum samples will be stored frozen for potential future analysis.  
m Subjects will consume 1  serving of Ensure Original VanillaÂ® breakfast drink (Abbott Laboratories:  220 calories, 32  g of total carbohydrate) at approximately 
9:[ADDRESS_364384] the time of  the start and completion of the meal.  The entire serv ing should be consumed within 5 minutes.  
n PPG blood glucose sample will be collected 2  hours Â± [ADDRESS_364385] drink  
 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 85 of 101  APPENDIX 2. SPONSOR SIGNATURE  
[CONTACT_2759]:  A Randomized, Double-Blind, Parallel Group Study to Evaluate the 
Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-
Dose Combination Compared to Ezetimibe and Placebo in Subjects With 
Type  2 Diabetes  and Ele vated LDL -Cholesterol 
Study Number:  1002FDC-[ADDRESS_364386] to critical review and has been approved by [CONTACT_456].  
The following contributed to writing and/or approving this protocol: 
 
 (e-signature [CONTACT_241039] )   
 Date  
 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 86 of 101  APPENDIX 3. INVESTIGATOR SIGNATURE  
[CONTACT_2759]:  A Randomized, Double-Blind, Parallel Group Study to Evaluate the 
Efficacy and Safety of Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed-
Dose Combination Compared to Ezetimibe and Placebo in Subjects With 
Type  2 Diabetes  and Elevated LDL-Cholesterol 
Study Number:  1002FDC-[ADDRESS_364387] the study as described in the protocol. 
 
   
Name: 
[CONTACT_1641] : 
Affiliation : 
Address: Phone :  
Fax:  Date  
 
  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 87 of 101  APPENDIX 4. SUMMARY OF CHANGES AMENDMENT 1 
 
SUMMARY OF CHANGES 
CLINICAL STUDY PROTO COL  
Study Number:  1002FDC -058 
Study Title:  A Randomized, Double-Blind, Parallel Group Study to 
Evaluate the Efficacy and Safety of Bempedoic Acid 
180 mg + Ezetimibe [ADDRESS_364388] s with 
Type 2 Diabetes and Elevated  LDL-C   
Protocol Version Incorporating Current Summary of Changes:  Amendment 1:  14 March 2018 
Preceding Protocol Version:  Original Protocol:  [ADDRESS_364389] Name: [CONTACT_298582] 180 mg + Ezetimibe 10 mg FDC 
Conventions used in this Summary of Changes Document  
â€¢ The text immediately preceding and following a change to the protocol is included for 
each change in order to provide the reviewer with a reference point to identify the change in the protocol. 
â€¢ All locations ( i.e., secti on numbers and/or header text) refer to the current protocol 
version, which incorporates the items specified in this Summary of Changes document. 
â€¢ The original text is from the preceding protocol version. 
â€¢ In the â€œNew Textâ€, all substantive text added to the protocol is bolded and italicized. 
â€¢ In the â€œNew Textâ€, text deleted from the protocol is indicated in strikethrough font. 
Summary and Justification of Changes 
The protocol was amended for the following: 
1. Added a line for Amendment [ADDRESS_364390] amendment version 
details.  
3. Revised text to indicate that IMP should be taken â€œin the morningâ€ in the Synopsis and 
Section  7.[ADDRESS_364391] ions of the protocol   
4. Revised  text to indicate subjects may take IMP â€œwith or without foodâ€ rather than after a 
minimum [ADDRESS_364392]â€ in S ections  7.1 and 9.2.1 (Table 1) for consistency across all 
sections of the protocol.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 88 of 101  5. Revised text to indicate container for IMP are â€œblister cards with child -resistant closuresâ€ 
rather than â€œHDPE container with screw -on, child-proof capâ€ in Section 9.2.1 (Table 1) 
and removed references to HDPE in Section s 4 and 9.2.1 (Table 1) to reflect final 
packaging of IMP.  
6. Revised text to remove general order of scheduled assessments at study visits  (unless 
otherwise specified) ; and to indicate scheduled assessments should be completed on 
subjects while fasted and prior to taking study medication in Section  11.5 for clarity on 
intended general visit guidelines. 
7. Specified that FSH is for women â€œ<55  years old and â‰¥1 year without mensesâ€ in 
Synopsis â€œOther Assessmentsâ€ subsection, Section  11.6.1, Section  13.6.1 Table 3, and 
Appendix 1 footer super script â€œfâ€ for consistency acros s all sections of the protocol. 
8. For s tudy procedures and schedule of assessments, added â€œweight (in kilograms) will be 
recordedâ€ for Visit  T1 ( Section  11.7.1) and Visit T3/EOS ( Section  11.7.3) for consistency 
across all sections of the protocol. 
9. Remove references to Pharmaco kinetic (PK) samples in Sections  12.1.5, 12.1.6, 
and 13.6.[ADDRESS_364393] study visit in Section  [IP_ADDRESS] for consistency across all 
sections of the protocol. 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 89 of 101  CHANGE 1: REVISION OF TITLE PAGE VERSION INFORMATION 
Location: 
Title Page: Version  
Original Text:  
 Version  Date   
 Original Protocol  18 December 2017 (Final)   
New Text:  
 Version  Date   
 Original Protocol  18 December 2017 (Final)  
 Amendment 1  14 March 2018   
 
CHANGE 2: REVISION OF PAGE HEADER VERSION INFORMATION  
Location: Page headers , all pages 
Original Text:  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Original Protocol, Final, 18 December 2017 
New Text:  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018  
  Original Protocol, Final, 18 December 2017 
 
CHANGE 3: INDICATE THAT IMP  SHOULD BE TAKEN â€œIN THE MORNINGâ€  
Location: Synopsis; Subsection Study Design 
Original Text:  
Subjects will report to the study site for the first treatment visit (Visit T1/Day  1) after a minimum 
10-hour fast.  Subjects who continue to meet the study inclus ion/exclusion criteria will be 
randomized in a 1:1:1 ratio to receive either FDC (n  = 56), EZE (n = 56), or PBO (n  = 56) once 
daily  for 12  weeks.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 90 of 101  New Text:  
Subjects will report to the study site for the first treatment visit (Visit T1/Day  1) after a minimum 
10-hour fast.  Subjects who continue to meet the study inclusion/exclusion criteria will be 
randomized in a 1:1:1 ratio to receive either FDC (n  = 56), EZE (n = 56), or PBO (n  = 56) once 
daily  in the morning  for 12  weeks.  
 
Location: 
Synopsis; Subsection IMP Dosage and Mode of Administration 
Original Text:  
Bempedoic acid 180 mg + EZE 10 mg FDC tablets, EZE 10 mg overencapsulated tablets, and 
FDC -matching PBO tablet, and EZE -matching PBO capsules will be supplied by [CONTACT_298546].  All IMP will be ingested once daily at a similar time with or without food.  
New Text:  
Bempedoic acid 180 mg + EZE 10 mg FDC tablets, EZE 10 mg overencapsulated tablets, and 
FDC -matching PBO tablet, and EZE -matching PBO capsules will be supplied by [CONTACT_298546].  A ll IMP will be ingested once daily at a similar time in the morning  with or 
without food. 
 
Location: 
Section 7.1 
Original Text:  
Subjects will report to the study site for the first treatment visit (Visit T1/Day  1) after a minimum 
10-hour fastâ€¦Subjects will be dispensed IMP at Visit T1/Day  [ADDRESS_364394] 
(only water allowed) and to continue fasting for 1 hour after ingesting the IMP. 
New Text:  
Subjects will report to the study site for the first treatment visit (Visit T1/Day  1) after a minimum 
10-hour fastâ€¦  Subjects will be dispensed IMP at Visit T1/Day  [ADDRESS_364395] (only water allowed) and to continue fasting for 1 hour after ingesting the 
IMP with or without food.  
 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 91 of 101  CHANGE 4: INDICATE SUBJECTS MAY TAKE IMP â€œWITH OR WITHOUT FOODâ€  
Location: 
Section 7.1 
Original Text : 
Subjects will report to the study site for the first treatment visit (Visit T1/Day  1) after a minimum 
10-hour fastâ€¦Subjects will be dispensed IMP at Visit T1/Day  [ADDRESS_364396] 
(only water allowed) and to continue fasting for 1 hour after ingesting the IMP. New Text:  
Subjects will report to the study site for the first treatment visit (Visit T1/Day  1) after a minimum 
10-hour fastâ€¦  Subjects will be dispensed IMP at Visit T1/Day  [ADDRESS_364397] (only water allowed) and to continue fasting for 1 hour after ingesting the 
IMP with or without food.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058 Amendment 1, 14 March 2018 
 
 
Confidential Page 92 of 101  Location: 
Section 9.2.1 (Table 1) 
Original Text:  
Parameter Bempedoic Acid + Ezetimibe 
FDC Tablet  Ezetimibe Overencapsulated Tablet  FDC- matched Placebo Tablet  Ezetimibe- matched Placebo 
Capsule  
Dosage form:  Film -coated tablet  Over -encapsulated tablets  Film -coated tablet  Capsules  
Unit dose:  180 mg bempedoic acid + 
10 mg ezetimibe 10 mg Not applicable  Not applicable  
Container:  HDPE container with screw -on, 
child proof cap  HDPE container with screw -on, 
child proof cap  HDPE container with screw -on, 
child proof cap  HDPE container with screw -on, 
child proof cap  
Route of administration:  Oral with water after a minimum 
[ADDRESS_364398]  
Physical description: 
New Text:  
Parameter Bempedoic Acid + Ezetimibe FDC Tablet  Ezetimibe Overencapsulated Tablet  FDC- matched Placebo Tablet  Ezetimibe- matched Placebo 
Capsule  
Dosage form:  Film -coated tablet  Over -encapsulated tablets  Film -coated tablet  Capsules  
Unit dose:  180 mg bempedoic acid + 
10 mg ezetimibe 10 mg Not applicable  Not applicable  
Container:  HDPE container with screw -on, 
child  proof cap Blister cards 
with child -resistant closures  HDPE container with screw -on, 
child proof cap Blister cards 
with child -resistant closures  HDPE container with screw -on, 
child proof cap Blister cards 
with child -resistant closures  HDPE container with s crew -on, 
child proof cap Blister cards 
with child -resistant closures  
Route of administration:  Oral with water after a minimum 
[ADDRESS_364399]  with or without 
food 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058 Amendment 1, 14 March 2018 
 
 
Confidential Page 93 of 101  Parameter Bempedoic Acid + Ezetimibe 
FDC Tablet  Ezetimibe Overencapsulated Tablet  FDC- matched Placebo Tablet  Ezetimibe- matched Placebo 
Capsule  
Physical description: 
 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 94 of 101  CHANGE 5: INDICATE CONTAINER F OR IMP ARE â€œBLISTER CARDS WITH 
CHILD- RESISTANT CLOSURESâ€ AND REMOVE REFERENCES TO 
HDPE CONTAINERS  
Location: 
Section 4. List of Abbreviations and Definitions of Terms 
Original Text:  
HDL -C high-density lipoprotein cholesterol 
HDPE  high density polyethylene 
Hgb hemoglobin 
New Text:  
HDL -C high-density lipoprotein cholesterol 
HDPE  high density polyethylene 
Hgb hemoglobin 
 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058 Amendment 1, 14 March 2018 
 
 
Confidential Page 95 of 101  Location: 
Section 9.2.1 (Table 1) 
Original Text:  
Parameter Bempedoic Acid + Ezetimibe 
FDC Tablet  Ezetimibe Overencapsulated Tablet  FDC- matched Placebo Tablet  Ezetimibe- matched Placebo 
Capsule  
Dosage form:  Film -coated tablet  Over -encapsulated tablets  Film -coated tablet  Capsules  
Unit dose:  180 mg bempedoic acid + 
10 mg ezetimibe 10 mg Not applicable  Not applicable  
Container:  HDPE container with screw -on, 
child proof cap  HDPE container with screw -on, 
child proof cap  HDPE container with screw -on, 
child proof cap  HDPE container with screw -on, 
child proof cap  
Route of administration:  Oral with water after a  minimum 
[ADDRESS_364400]  
Physical description: 
FDC = fixed -dose combination ; HDPE = high density polyethylene  
New Text:  
Parameter Bempedoic Acid + Ezetimibe 
FDC Tablet  Ezetimibe Overencapsulated Tablet  FDC- matched Placebo Tablet  Ezetimibe- matched Placebo 
Capsule  
Dosage form:  Film -coated tablet  Over -encapsulated tablets  Film -coated tablet  Capsules  
Unit dose:  180 mg bempedoic acid + 
10 mg ezetimibe 10 mg Not applicable  Not applicable  
Container:  HDPE container with screw -on, 
child proof cap Blister cards 
with child -resistant closures  HDPE container with screw -on, 
child proof cap Blister cards 
with child -resistant closures  HDPE container with screw -on, 
child proof cap Blister cards 
with child -resistant closures  HDPE container with screw -on, 
child proof cap Blister cards 
with child -resistant closures  

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058 Amendment 1, 14 March 2018 
 
 
Confidential Page 96 of 101  Parameter Bempedoic Acid + Ezetimibe 
FDC Tablet  Ezetimibe Overencapsulated Tablet  FDC- matched Placebo Tablet  Ezetimibe- matched Placebo 
Capsule  
Route of administration:  Oral with wate r after a minimum 
[ADDRESS_364401]  with or without 
food 
Physi cal 
description: 
FDC = fixed -dose combination; HDPE = high density polyethylene . 
 

Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 97 of 101  CHANGE 6: CLARIFICATION OF INTENDED GENERAL VISIT GUIDELINES   
Location:  
Section 11.5 
Original Text:  
When multiple procedures are scheduled for the same visit, the following order should be 
followed (unless otherwise specified) : 
New Text:  
When multiple procedures are scheduled for the same visit, the following order should be 
followed Subjects will arrive fasted and having not taken study medication prior to the visit. 
The following assessments will be conducted while fasted and prior to taking study medication  
(unless otherwise specified): 
 
CHANGE 7: CLARIFY THAT FSH IS FOR WOME N â€œ<55 YEARS OLD AND 
>1 YEAR WITHOUT MENSESâ€   
Location:  
Synopsis; Subsection Criteria for evaluation, Other Assessments 
Original Text:  
HBsAg, HCV, serum (Visit  S1) and urine (Visit T1) pregnancy test (only for females who are of 
childbearing potential), FSH (only for postmenopausal females <55 years), TSH.  Reserve blood 
samples (serum and plasma) for potential future measurement of potential biomarkers (Visit T1, 
T3). 
New Text:  
HBsAg, HCV, serum (Visit  S1) and urine (Visit T1) pregnancy test (only for females who are of 
childbearing potential), FSH (only for postmenopausal females women <55 years  old and 
â‰¥1 year without menses ), TSH.  Reserve blood samples (serum and plasma) for potential future 
measurement of potential biomarkers (Visit T1, T3). 
 
Location:  
Section 11.6.1 
Original Text:  
â€¢ Blood and ur ine specimens will be obtained for the following:  
âˆ’ serum pregnancy test (for surgically sterile women and women of childbearing 
potential) or FSH test ( postmenopausal women); 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 98 of 101  New Text:  
â€¢ Blood and urine specimens will be obtained for the following: 
âˆ’ serum preg nancy test (for surgically sterile women and women of childbearing 
potential) or FSH test ( postmenopausal women  <55 years old and â‰¥1 year 
without menses ); 
 
Location:  
Section 13.6.1, Table 3 
Original Text:  
Other Screening Labs 
â€¢ Hepatitis B surface antigen (HBsAg)  
â€¢ Hepatitis C virus (HCV)b 
â€¢ Serum pregnancy test (only for females of childbearing potential)  
â€¢ Follicle -stimulating hormone (FSH; Females <55 years and >1 year without menses)  
â€¢ Urine pregnancy test prior to randomization (for female of child bearing pot ential)  
â€¢ Thyroid-stimulating hormone (TSH) 
New Text:  
Other Screening Labs 
â€¢ Hepatitis B surface antigen (HBsAg) 
â€¢ Hepatitis C virus (HCV)b 
â€¢ Serum pregnancy test (only for females of childbearing potential)  
â€¢ Follicle -stimulating hormone (FSH; Females <55 years and > â‰¥1 year without menses)  
â€¢ Urine pregnancy test prior to randomization (for female of child bearing potential) 
â€¢ Thyroid-stimulating hormone (TSH) 
 
Location:  
Appendix 1. Schedule of Assessments; Footer Superscript â€œfâ€ 
Original Text:  
f Pregnancy tests will be obtained for women of childbearing potential and for surgically sterile 
women; FSH level will be obtained for postmenopausal women . 
New Text:  
f Pregnancy tests will be obtained for women of childbearing potential and for surgically sterile women; FSH level will be obtained for postmenopausal women  <55 years old and â‰¥1 year 
without menses . 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 99 of 101  CHANGE 8: ADD â€œWEIGHT (IN KILOGRAM S) WILL BE RECORDEDâ€  FOR 
VISIT  T1 (SECTION  11.7.1) AND VISIT T3/EOS (SECTION  11.7.3)  
Location:  
Section 11.7.1 
Original Text:  
â€¢ Adverse event s will be assessed.  
â€¢ Vital signs (systolic blood pressure, diastolic blood pressure, and pulse rate) will be 
recorded.  
New Text:  
â€¢ Adverse event s will be assessed.  
â€¢ Weight (in kilograms) will be recorded . 
â€¢ Vital signs (systolic blood  pressure, diastolic blood pressure, and pulse rate) will be 
recorded.  
 
Location:  
Section 11.7.3 
Original Text:  
â€¢ Adverse event s will be assessed.  
â€¢ PE. 
New Text:  
â€¢ Adverse event s will be assessed.  
â€¢ Weight (in kilograms) will be recorded . 
â€¢ PE. 
 
CHANGE 9: REMOVE REFERENCES TO PK SAM PLES  
Location:  
Section 12.1.5 
Original Text:  
Additional exploratory safety, efficacy, PK, or potential biomarkers may be assayed from serum 
and plasma blood samples collected at Visits  T1 and T3 and stored frozen, reserved for potentia l 
future measurement of potential biomarkers.  
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 100 of 101  New Text:  
Additional exploratory safety, efficacy, PK,  or potential biomarkers may be assayed from serum 
and plasma blood samples collected at Visits  T1 and T3 and stored frozen, reserved for potential 
future measurement of potential biomarkers.  
 
Location:  
Section 12.1.6 
Original Text:  
Blood specimens for PK laboratory assessments will be collected as shown in Table 2. 
New Text:  
Blood specimens for PK  basic fasting lipi[INVESTIGATOR_805], special lipi[INVESTIGATOR_805], and other biomarker laboratory 
assessments will be collected as shown in Table 2. 
 
Location:  
Section 13.6.4 
Original Text:  
The total number of venipunctures and total volume of blood collected during the study will be 
limited to that needed for  PK and safety assessments.   
New Text:  
The total n umber of venipunctures and total volume of blood collected during the study will be 
limited to that needed for  PK and  safety assessments.   
 
CHANGE 10: CORRECT REPORTING REQUIREMENTS FOR AES TO THE PERIOD 
OF THE T IME OF ICF IS SIGNED THROUGH [ADDRESS_364402] STUDY VISIT  
Location:  
Section 13.6.1, Table 3 
Original Text:  
Coagulation (Visit S1 for all subjects, Visit T1 and 
3-5 days after Visit T1 in subjects receiving 
anticoagulation therapy only) 
â€¢ Prothrombin time (PT)  
â€¢ International normalized ratio (INR) 
Bempedoic Acid 180 mg + Ezetimibe  10 mg  
Fixed -Dose Combination  Esperion Therapeutics, Inc. 
Clinical Study Protocol 1002FDC-058  Amendment 1, 14 March 2018 
 
 
Confidential Page 101 of 101  New Text:  
Coagulation (Visit S1 for all s ubjects, Visit T1 and 
3-57 days after Visit  T1 in subjects receiving 
anticoagulation therapy only) 
â€¢ Prothrombin time (PT) 
â€¢ International normalized ratio (INR) 
 
CHANGE 11: CORRECT REPORTING REQUIREMENTS FOR AES TO THE PERIOD 
OF THE TIME OF ICF IS SIGNED THROUGH [ADDRESS_364403] STUDY VISIT  
Location:  
Section [IP_ADDRESS] 
Original Text:  
All AEs that occur from the time the ICF is signed through [ADDRESS_364404] study visit should be reported to the sponsor per Section  [IP_ADDRESS].   
New Text:  
All AEs that occur from the time the ICF is signed through [ADDRESS_364405] study visit should be reported to the sponsor per Section  
[IP_ADDRESS].   
 
Signature [CONTACT_11032]-CLIN-000963 vO.l 
I Approval 
15-Mar-2018 22:18:34 GMT+OOOO 
I Approval 
15-Mar-2018 22:24:48 GMT+OOOO 
I Approval 
15-Mar-2018 23:13:47 GMT+OOOO 
I Approval 
16-Mar-2018 02:10:33 GMT+OOOO 
I Approval 
16-Mar-2018 17:48:08 GMT+OOOO 
I Approval 
18-Mar-2018 19:55:56 GMT+OOOO 
I Approval 
20-Mar-2018 17:55:50 GMT+OOOO 
Signature [CONTACT_11032]-CLIN-000963 v0.1 